

09/29/00

10-2-00

PTO/SB/05 (2/98)

Approved for use through 09/30/2000. OMB 0651-0032

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

A  
Box  
09/29/00

Please type a plus sign (+) inside this box →

+

**UTILITY  
PATENT APPLICATION  
TRANSMITTAL**

(Only for new nonprovisional applications under 37C.F.R. §1.53(b))

Attorney Docket No.

PC10555A

First Named Inventor or Application Identifier

Kendall Wayne King et al.

Title

NUCLEIC ACIDS AND PROTEINS OF THE MYCOPLASMA  
HYOPNEUMONIAE mhp3 GENE AND USES THEREOF

Express Mail Label No.

EJ 621330383US

**APPLICATION ELEMENTS**

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO:

Assistant Commissioner for Patents  
Box Patent Application  
Washington, DC 20231

1. ☒ \*Fee Transmittal Form (e.g., PTO/SB/17)  
(Submit an original, and a duplicate for fee processing)
2. ☒ Specification [Total Pages (preferred arrangement set forth below)
- Descriptive title of the Invention
  - Cross References to Related Applications
  - Statement Regarding Fed sponsored R&D
  - Reference in Microfiche Appendix
  - Background of the Invention
  - Brief Summary of the Invention
  - Brief Description of the Drawings (if filed)
  - Detailed Description
  - Claim(s)
  - Abstract of the Disclosure
3. ☒ Drawing(s) (35 U.S.C. 11.3) [Total sheets 

4. ☒ Oath or Declaration [Total pages 
  - a. ☐ Newly executed (original or copy)
  - b. ☐ Copy from a prior application (37 CFR §1.63(d))  
(for continuation/divisional with Box 17 completed)  
[Note Box 5 below]
  - i. ☐ DELETION OF INVENTOR(S)  
Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §§1.63(d)(2) and 1.33(b).

5. ☐ Incorporation By Reference (useable if Box 4b is checked)  
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered to be part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

6. ☐ Microfiche Computer Program (Appendix)
7. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
- a. ☒ Computer Readable Copy
  - b. ☒ Paper Copy (identical to computer copy)
  - c. ☒ Statement verifying identity of above copies

**ACCOMPANYING APPLICATION PARTS**

8. ☐ Assignment Papers (cover sheet & document(s))
9. ☐ 37 C.F.R. §3.73(b) Statement ☐ Power of Attorney  
(when there is an assignee)
10. ☐ English Translation Document (if applicable)
11. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
12. ☒ Preliminary Amendment
13. ☒ Return Receipt Postcard (MPEP 503)  
(Should be specifically itemized)
14. ☐ \*Small Entity ☐ Statement filed in prior application, Status still proper and desired (PTO/SB/09-12)
15. ☐ Certified Copy of Priority Document(s)  
(if foreign priority is claimed)
16. ☒ Other: 1. Priority Claim  
Priority claimed from provisional application 60/156,602, filed September 29, 1999.  
2. Petition under 37 C.F.R. 1.84(b) for Submission of Photographs as Formal Drawings

\*NOTE FOR ITEMS 1 & 14: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).

17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No: 60/ 156,602

Prior application information:

Examiner

Group/Art Unit:

**18. CORRESPONDENCE ADDRESS**☐ Customer Number or Bar Code Label (Insert Customer No. or Attach bar code label here) or ☒ Correspondence address below

Name	Paul H. Ginsburg				
Address	Pfizer Inc				
Address	235 East 42nd Street, 20th Floor				
City	New York	State	New York	Zip Code	10017-5755
Country	United States Of America	Telephone	(212)573-2369	Fax	(212)573-1939

NAME (Print/type) Jeffrey N. Myers

Registration No. (Attorney/Agent)

41,213

Signature

Date

September 29, 2000

# FEE TRANSMITTAL

Patent fees are subject to annual revision on October 1.  
These are the fees effective October 1, 1997.

Small Entity payments must be supported by a small entity statement,  
otherwise large entity fees must be paid. See Forms PTO/SB/09-12.

See 37 C.F.R. §§ 1.27 and 1.28.

Total Amount of Payment (\$)**972.00**

## Complete if Known

Application Number Not Yet Assigned  
Filing Date Herewith  
First Named Inventor Kendall Wayne King  
Examiner Name Not Yet Assigned  
Group/Art Unit Not Yet Assigned  
Attorney Docket No. PC 10555A

### METHOD OF PAYMENT (check one)

1. ☒ The commissioner is hereby authorized to charge indicated fees and credit any over payments to:
- Deposit Account Number 16-1445
- Deposit Account Name Pfizer Inc.
- ☒ Charge Any Additional Fee Required Under 37 C.F.R. §§ 1.16 and 1.17. ☐ Charge the Issue Fee Set in 37 C.F.R. § 1.18 at the Mailing of the Notice of Allowance.

2. ☐ Payment Enclosed:
- ☐ Check ☐ Money Order ☐ Other

### FEE CALCULATION

#### 1. BASIC FILING FEE

Large Entity Fee Code	Large Entity Fee (\$)	Small Entity Fee Code	Small Entity Fee (\$)	Fee Description	Fee Paid
101	690	201	345	Utility filing fee	690.00
106	310	206	155	Design filing fee	
107	480	207	240	Plant filing fee	
108	690	208	345	Reissue filing fee	
114	150	214	75	Provisional filing fee	

SUBTOTAL (1) (\$) 690.00

#### 2. EXTRA CLAIM FEES

Total Claims	Extra Claims	Fee from below	Fee Paid
27	-20**= 7	18	126.00
Independent Claims 5	-3**= 2	78	156.00
Multiple Dependent			

\*\* or number previously paid, if greater; For Reissues, see below

Large Entity Fee Code	Large Entity Fee (\$)	Small Entity Fee Code	Small Entity Fee (\$)	Fee Description
103	18	203	9	Claims in excess of 20
102	78	39		Independent claims in excess of 3
104	260	204	130	Multiple dependent claim, if not paid
109	78	209	39	**Reissue independent claims over original patent
110	18	210	9	**Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$) 282.00

### FEE CALCULATION (continued)

#### 3. ADDITIONAL FEES

Large Entity Fee Code	Large Entity Fee (\$)	Small Entity Fee Code	Small Entity Fee (\$)	Fee Description	Fee Paid
105	130	205	65	Surcharge - late fee or oath	
127	50	227	25	Surcharge-late provisional filing fee or cover sheet	
139	130	139	130	Non-English specification	
147	2,520	147	2,520	For filing a request for reexamination	
112	920*	112	920*	Requesting publication of SIR prior to Examiner action	
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	
115	110	215	55	Extension for reply within first month	
116	380	216	190	Extension for reply within second month	
117	870	217	435	Extension for reply within third month	
118	1,360	218	680	Extension for reply within fourth month	
128	1,850	228	925	Extension for reply within fifth month	
119	300	219	150	Notice of Appeal	
120	300	220	150	Filing a brief in support of an appeal	
121	260	221	130	Request for oral hearing	
138	1,510	138	1,510	Petition to institute a public use proceeding	
140	110	240	55	Petition to revive - unavoidable	
141	1,210	241	605	Petition to revive - unintentional	
142	1,210	242	605	Utility issue fee (or reissue)	
143	430	243	215	Design issue fee	
144	580	244	290	Plant issue fee	
122	130	122	130	Petitions to the Commissioner	
123	50	123	50	Petitions related to provisional applications	
126	240	126	240	Submission of Information Disclosure Statement	
581	40	581	40	Recording each patent assignment per property (times number of properties)	
146	790	246	395	Filing a submission after final rejection (37 CFR 1.129(a))	
149	760	249	380	For each additional invention to be examined (37 CFR 1.129(b))	
Other Fee (specify)					
Other Fee (specify)					

\*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$) 0.00

### SUBMITTED BY

Type or Printed Name Jeffrey N Myers

Signature

Date

September 29, 2000

### Complete (if Applicable)

Reg. Number 41,213

Deposit Account 16-1445

User ID

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: \_\_\_\_\_ :  
KENDALL WAYNE KING ET AL.

APPLICATION NO.: NOT YET ASSIGNED : Examiner: NOT YET ASSIGNED

FILING DATE: HEREWITH : Group Art Unit: NOT YET ASSIGNED

TITLE: NUCLEIC ACIDS AND PROTEINS :  
OF THE MYCOPLASMA  
HYOPNEUMONIA MHP3 GENE  
AND USES THEREOF  
\_\_\_\_\_

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

PRELIMINARY AMENDMENT

Please amend the subject application as follows:

In the claims:

Please cancel claims 12 – 17 and claims 34 – 44.


In the specification, at page 1, line 1, please insert:

-- CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional. Application No.  
60/156,602, filed September 29, 1999. --

Respectfully submitted,

Date: September 29, 2000

  
Jeffrey N. Myers  
Attorney for Applicant  
Reg. No. 41,213

Pfizer, Inc  
Patent Department, 20th Floor  
235 East 42nd Street  
New York, NY 10017-5755  
(212) 733-5061

NUCLEIC ACIDS AND PROTEINS OF THE MYCOPLASMA HYOPNEUMONIAE  
mhp3 GENE AND USES THEREOF

5       The *mhp3* gene codes for a protein of *Mycoplasma hyopneumoniae*. The present invention relates to nucleotides and proteins of *mhp3*. The present invention further relates to novel apoprotein antigens encoded by *mhp3* for use in vaccines to prevent and treat diseases caused by infection with *Mycoplasma hyopneumoniae*, and methods for the recombinant production of such antigens.

10

15

20

30

35

International Patent Publication WO 96/28472 identifies six protein antigen species of *M. hyopneumoniae* at molecular weights of 46-48, 52-54, 60-64, 72-75, 90-94 and 110-114 kilodaltons, and discloses partial protein sequences of the 52-54, 60-64 and 72-75 kilodalton

EXPRESS MAIL # ES62133038345

antigens and the full length nucleotide and amino acid sequences of the 46-48 kilodalton antigen. The 46-48 kilodalton antigen, to which we will refer hereinafter as P46, corresponds to the 44 kilodalton antigen of U.S. Patent No. 5,252,328 to Faulds and a 48 kilodalton antigen described in Lee (Lee et al., 1996, J. Chromatogr. A. 737:273-279), as determined on the basis of Faulds' and Lee's disclosures of partial peptide sequences. The gene encoding P46, *i.e.* *p46*, was also cloned by Futo *et al.* (1995; J. Bacteriol 177:1915-1917). Later, the same group showed that the *in vitro* expressed gene product was useful in diagnosing antibody responses to *M. hyopneumoniae* infections without cross reactivity to other *Mycoplasma* species (Futo *et al.*, 1995, J. Clin. Microbiol. 33:680-683). The sequences and diagnostic uses of the *p46* gene described by Futo *et al.* are further disclosed in European Patent Publication No. 0 475 185 A1.

The partial peptide sequence of the 60-64 kilodalton antigen of WO 96/28472 has significant homology to a protein called P102 (see below). In addition, the antigen has significant homology to a 64 kilodalton antigen disclosed by Faulds (U.S. Patent No. 5,252,328).

The 72-75 kilodalton antigen of WO 96/28472 corresponds to a 65 kilodalton protein disclosed by Wise and Kim (1987, J. Bacteriol., 169:5546-5555 and U.S. Patent No. 5,788,962) and will be referred to hereinafter as P65.

The 52-54 kilodalton antigen, to which we will refer hereinafter as Mhp3, may correspond to the 50 kilodalton integral membrane protein described by Wise and Kim (1987, J. Bacteriol., 169:5546-5555) and/or the 52 kilodalton protein species disclosed in Faulds (U.S. Patent No. 5,252,328). The 52-54 kilodalton antigen is termed hereinafter MHP3. WO 96/28472 discloses the sequences of the amino terminus of the mature protein and of an internal cyanogen bromide fragment.

The 90-94 kilodalton antigen of WO 96/28472 may correspond to the adhesin *p97* as disclosed by Hsu *et al.*, which is described below.

WO 96/28472 further discloses the results of vaccine trials using the 60-64 kilodalton antigen, P46 or a combination of P65 and Mhp3. The vaccinations elicited significant protection from *M. hyopneumoniae* infection.

There are multiple reports concerning outer membrane proteins of *M. hyopneumoniae* in the scientific and patent literature. For example, Wise and Kim (1987, J. Bacteriol., 169:5546-5555) report that there are four integral membrane protein species in *M. hyopneumoniae*, named *p70*, *p65* (P65, *supra*), *p50* and *p44*, and that the latter three are modified by covalent lipid attachments and induce a strong humoral immune response. The protective effects of the immune response were not investigated. The gene encoding the P65 protein was cloned, and its sequences and their uses, for example in vaccines and diagnostics are described in U.S. Patent No. 5,788,962.

International Patent Publication WO 91/15593 discloses five proteins of *M. hyopneumoniae* of apparent molecular weights of 105, 90, 85, 70 and 43 kilodaltons. A full length sequence of the gene encoding 85 kilodalton protein (protein C) was provided, as were partial nucleotide sequences encoding the other four proteins. Vaccine trials using protein C  
5 afforded the test animals 'significant' protection against *M. hyopneumoniae*.

U.S. Patent No. 5,252,328 to Faulds discloses amino terminal sequences of immunoreactive *M. hyopneumoniae* proteins, the molecular weights of which are 36, 41, 44, 48, 64, 68, 74.5, 79, 88.5, 96 and 121 kilodaltons. Other proteins identified based on the electrophoretic mobilities but for which no protein sequences were disclosed had apparent  
10 molecular weights of 22.5, 34 and 52 kilodaltons. While U.S. Patent No. 5,252,328 proposed the use of these proteins in vaccine formulations, no results of vaccine trials were reported.

International Patent Publication WO 95/09870 discloses biochemical methods for the purification of *M. hyopneumoniae* adhesins, the mycoplasmal integral membrane proteins responsible for adhesion to the cilia of the host's upper respiratory epithelium. WO 95/09870  
15 also proposes assays and uses for these proteins, for example in vaccines and diagnostics. However, no cloning of adhesin genes was reported until a gene termed *p97* was cloned and its product, hereinafter "P97", shown to play a role in the organism's ability to bind to ciliated cells within the respiratory tract of *M. hyopneumoniae*-infected swine (Hsu *et al.*, 1997, J. Bacteriol. 179:1317-1323). A research paper by King *et al.* (1997; Vaccine 15:25-35)  
20 disclosed Mhp1, a 124 kilodalton adhesin that is a strain variant of P97. However, attempts to vaccinate pigs against *M. hyopneumoniae* using an GST-Mhp1 fusion protein did not result in statistically significant protection against enzootic mycoplasmal pneumonia. A 94 kilodalton variant of P97 was identified by Wilton *et al.* (1998, Microbiology 144:1931-1943). Additionally, the *p97* gene was shown to be part of an operon that also encodes a second  
25 protein, termed P102, of a predicted molecular weight of approximately 102 kilodaltons (Hsu *et al.*, 1998, Gene 214:13-23). Minion and Hsu suggest the use of P102 in vaccines in the international patent publication WO 99/26664 but do not report vaccine trials.

## SUMMARY OF THE INVENTION

The present invention encompasses nucleotides and proteins of the *M. hyopneumoniae* *mhp3* gene. The present invention also encompasses novel apoprotein antigens encoded by the *mhp3* gene for use in vaccines to prevent and treat diseases caused by infection with *M. hyopneumoniae*. Methods for the recombinant production of apo-Mhp3 are also provided.

The invention provides a vaccine formulation comprising a polypeptide comprising an amino acid sequence as set forth to SEQ ID NO:2, or any fragment thereof that consists of at least 10, at least 20, at least 30, at least 40, at least 50 or at least 100 contiguous amino acids, and a pharmaceutically acceptable carrier. In certain embodiments, the vaccine further comprises at least one other immunogenic or antigenic polypeptide, which other polypeptide can be viral, bacterial or parasitic in origin. In a preferred embodiment, the vaccine further comprises at least one polypeptide selected from the group consisting of *M. hyopneumoniae* P46, P65, P97 and P102 proteins and fragments, variants and derivatives thereof.

The invention provides a vaccine formulation comprising an antigenic or immunogenic polypeptide comprising an amino acid sequence corresponding to SEQ ID NO:4, or any derivative, variant or fragment thereof, and a pharmaceutically acceptable carrier. In a preferred embodiment, the antigenic or immunogenic polypeptide is expressed as a thioredoxin fusion protein, preferably by cloning into the expression vector pBAD/Thio-TOPO, and produced by an *E. coli* BL21 strain. In a highly preferred embodiment, the vaccine further comprises at least one polypeptide selected from the group consisting of *M. hyopneumoniae* P46, P65, P97 and P102 and fragments, variants and derivatives thereof.

The invention provides a method of treating or preventing a disease or disorder in an animal caused by infection with *M. hyopneumoniae* comprising administering to the subject a vaccine formulation comprising an antigenic or immunogenic polypeptide comprising an amino acid sequence corresponding to SEQ ID NO:2, or any apo derivative, variant or fragment thereof, and a pharmaceutically acceptable carrier, in an amount sufficient to elicit an increase in *M. hyopneumoniae* specific cellular or humoral responses. In a preferred embodiment, the amino acid sequence is as set forth in SEQ ID NO:4. In another preferred embodiment, the animal is a pig.

The invention further provides kits for the detection of *M. hyopneumoniae*. In one embodiment, the kit provides reagents for the detection of circulating antibodies against *M. hyopneumoniae* Mhp3 protein. In another embodiment, the kit provides reagents for the detection of *M. hyopneumoniae* nucleic acids, either by polymerase chain reaction (PCR) or by hybridization methods.

This invention provides a protein having an amino acid sequence comprising at least 30 contiguous amino acids of SEQ ID NO:4, wherein said protein does not have a fatty acid

acylated cysteine followed by the amino acid sequence Trp Asp Lys Glu, and does not have a C-terminal homoserine lactone. In an embodiment, the protein has an amino acid sequence comprising at least 50 contiguous amino acids of SEQ ID NO:4. In another embodiment, the protein is a fusion protein. In a further embodiment, the fusion protein is a thioredoxin fusion protein.

This invention also provides a protein having an amino acid sequence comprising at least amino acids 1-30 of SEQ ID NO:4. In an embodiment, the protein has an amino acid sequence comprising SEQ ID NO:4.

This invention provides any of the above proteins, which is an isolated protein. This invention also provides a composition comprising any of the above proteins and a pharmaceutically acceptable carrier. In an embodiment, the composition further comprises an adjuvant. In another embodiment, the composition further comprises at least one polypeptide selected from the group consisting of *Mycoplasma hyopneumoniae* P46, P65, P97 and P102.

This invention provides an immunogenic protein having an amino acid sequence as depicted in SEQ ID NO:2, or a fragment, variant or derivative thereof, wherein the immunogenic protein does not have a fatty acid acylated cysteine followed by the amino acid sequence Trp Asp Lys Glu, and does not have a C-terminal homoserine lactone.

This invention provides an immunogenic protein having an amino acid sequence as depicted in SEQ ID NO:4, or a fragment, variant or derivative thereof, wherein the immunogenic protein does not have a fatty acid acylated cysteine followed by the amino acid sequence Trp Asp Lys Glu, and does not have a C-terminal homoserine lactone.

This invention provides a method of treating or preventing a disease or disorder in an animal caused by infection with *Mycoplasma hyopneumoniae* comprising administering to the animal a vaccine formulation comprising (i) a protein having an amino acid sequence comprising at least 30 contiguous amino acids of SEQ ID NO:4, wherein said protein does not have a fatty acid acylated cysteine followed by the amino acid sequence Trp Asp Lys Glu, and (ii) a pharmaceutically acceptable carrier, in an amount sufficient to elicit an increase in *Mycoplasma hyopneumoniae* specific cellular or humoral responses. In an embodiment, said protein has an amino acid sequence comprising at least 50 contiguous amino acids of SEQ ID NO:4.

This invention provides a method of treating or preventing a disease or disorder in an animal caused by infection with *Mycoplasma hyopneumoniae* comprising administering to the animal a vaccine formulation comprising (i) an antigenic or immunogenic protein having an amino acid sequence comprising at least amino acids 1-30 of SEQ ID NO:4, and (ii) a pharmaceutically acceptable carrier, in an amount sufficient to elicit an increase in *Mycoplasma hyopneumoniae* specific cellular or humoral responses. In an embodiment, said protein has an amino acid sequence comprising SEQ ID NO:4.



In an embodiment of any of the above methods, said animal is a pig.

This invention provides an isolated or purified DNA encoding in the mycoplasmal genetic code a protein having an amino acid sequence comprising at least 30 contiguous amino acids of SEQ ID NO:2, or its complement. In an embodiment, the protein has a sequence comprising at least 50 contiguous amino acids of SEQ ID NO:2. In another embodiment, the DNA has a sequence comprising at least 90 contiguous nucleotides of SEQ ID NO:1.

This invention provides a DNA encoding in the universal genetic code a protein having an amino acid sequence comprising at least 30 contiguous amino acids of SEQ ID NO:4, or its complement. In an embodiment, the protein has a sequence comprising at least 50 contiguous amino acids of SEQ ID NO:4. In another embodiment, the DNA has a sequence comprising at least 90 contiguous nucleotides of SEQ ID NO:3.

In other embodiments the above DNA is operably linked to a heterologous promoter. In this invention, DNA operably linked to a heterologous promoter is isolated DNA. In yet other embodiments, any one of the above DNAs further comprises an origin of replication active in a prokaryotic cell. In other embodiments, any one of the above DNAs further comprises an origin of replication active in a eukaryotic cell.

This invention provides a host cell comprising any of the above DNAs operably linked to a heterologous promoter. In an embodiment, the host cell is *E. coli* BL21 and said DNA is the expression vector pBAD/Thio-TOPO.

This invention provides a method for the production of apo-Mhp3 or a fragment thereof, said method comprising (i) growing the above cells under conditions wherein apo-Mhp3 is expressed, and (ii) recovering said protein. In an embodiment, said protein is recovered in a soluble form. In another embodiment, said protein is recovered in an insoluble form.

This invention provides a method of treating or preventing a disease or disorder in an animal caused by infection with *Mycoplasma hyopneumoniae* comprising administering to the animal a vaccine formulation comprising (i) any of the above DNAs, and (ii) a pharmaceutically acceptable carrier, in an amount sufficient to elicit an increase in *Mycoplasma hyopneumoniae* specific cellular or humoral responses. In an embodiment, said animal is a pig.

This invention provides an isolated DNA comprising a fragment of 15-40 nucleotides, which fragment hybridizes under stringent conditions for PCR to a DNA encoding in the mycoplasmal genetic code a protein having a sequence of at least 5 contiguous amino acids of SEQ ID NO:2, or its complement. In an embodiment, the hybridization is specific to *M. hyopneumoniae*.

5 This invention provides a kit comprising in at least one container a first isolated DNA comprising a fragment of at least 15 nucleotides, which fragment hybridizes under stringent conditions for PCR to a DNA encoding in the mycoplasmal genetic code a protein having a sequence of at least 5 contiguous amino acids of SEQ ID NO:2, and a second isolated DNA  
10 comprising a fragment of at least 15 nucleotides, which fragment hybridizes under stringent conditions for PCR to a DNA complementary to a DNA encoding in the mycoplasmal genetic code a protein having a sequence of at least 5 contiguous amino acids of SEQ ID NO:2, wherein said kit comprises a statement indicating that the kit is useful for diagnosis of *M. hyopneumoniae* infection. In an embodiment, the hybridization is specific to *M. hyopneumoniae*. In another embodiment, the kit comprises in at least one container any of  
15 the above isolated DNAs, wherein the hybridization is specific to *M. hyopneumoniae* and wherein said kit comprises a statement indicating that the kit is useful for diagnosis of *M. hyopneumoniae* infection.

This invention provides a kit comprising in at least one container a protein having an amino acid sequence comprising at least 30 contiguous amino acids of SEQ ID NO:4 and a statement indicating that the kit is useful for diagnosis of *M. hyopneumoniae* infection. In an embodiment, the kit further comprises an anti-pig secondary antibody, and in a further embodiment the secondary antibody is conjugated to an enzyme that catalyzes a colorimetric reaction. In a still further embodiment, the enzyme is selected from the group consisting of alkaline phosphatase and horseradish peroxidase, and in another still further embodiment, the kit further comprises reagents for a colorimetric assay.

## BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 is a Clustal W (1.7) sequence alignment between Mhp3 from *M. hyopneumoniae* (SEQ ID NO:2) and Ag234-5 (SEQ ID NO:41), originally thought to originate from *M. arginini* but later shown to be derived from *M. hyorhinis*. Amino acid identity is depicted by asterisks (\*), highly conservative substitutions are indicated by colons (:), and conservative substitutions indicated by periods (.). Overall, the two proteins share 36.2% amino acid identity.

FIG. 2 is a Western blot demonstrating reactivity of antibodies from a pig experimentally challenged with *M. hyopneumoniae* against protein extracts from *M. hyopneumoniae*, *M. hyorhinis*, or *M. mycoides*, or against purified recombinant Mhp3.

## ABBREVIATIONS AND DEFINITIONS

The abbreviation *M.*, where preceding the name of a species, refers to the genus *Mycoplasma*.

The term "recombinant *mhp3*" refers to a nucleic acid encoding the Mhp3 antigen in the universal genetic code. "*M. hyopneumoniae mhp3*" refers to a nucleic acid encoding the Mhp3 antigen in the *M. hyopneumoniae* genetic code. In *M. hyopneumoniae*, the codon TGA indicates a tryptophan residue rather than a translational stop codon. Thus, the recombinant *mhp3* gene differs from *M. hyopneumoniae mhp3* by having TGG codons instead of TGA codons.

The term "Mhp3" refers to a protein encoded by an *mhp3* gene.

The term "apoprotein" indicates a protein that is lacking a lipid moiety, for example by deletion or mutation of the amino acid that would function as an acceptor of said lipid moiety.

The term "ORF" indicates "open reading frame", *i.e.* the coding region of a gene.

"Percentage of sequence identity" for nucleic acids and polypeptides is determined by comparing two optimally aligned sequences over a comparison window, wherein optimal alignment provides the highest order match and may introduce additions or deletions to the test or reference sequence. The percentage identity is determined by calculating the percentage of amino acids that are identical in the test and reference sequence at a given position. Optimal sequence alignment and percentage identity may be determined manually, or more preferably by a computer algorithm including but not limited to TBLASTN, BLASTP, FASTA, TFASTA, GAP, BESTFIT, and CLUSTALW (Altschul et al., 1990, J. Mol. Biol. 215(3):403-10; Pearson and Lipman, 1988, Proc. Natl. Acad. Sci. USA 85(8):2444-8; Thompson, et al., 1994, Nucleic Acids Res. 22(22):4673-80; Devereux et al., 1984, Nuc. Acids. Res. 12:387-395); Higgins, et al., 1996, Methods Enzymol 266:383-402). Preferably, the NCBI Blast Server (<http://www.ncbi.nlm.nih.gov>) set at the default parameters is used to determine the percentage of sequence identity.

The term heterologous, when herein used to describe a promoter, indicates that the promoter is not native to the open reading frame whose expression it controls.

The term "isolated protein" indicates a composition of proteins in which the isolated protein comprises at least 50% by weight. More preferably, the composition comprises about 95%, and most preferably 99% by weight of the isolated protein.

The term "recovered in a soluble form" indicates that a protein or polypeptide is retrieved from the cytoplasm of the cell that expresses said protein or polypeptide.

The term "recovered in an insoluble form" indicates that a protein or polypeptide is retrieved from inclusion bodies present in the cell that expresses said protein or polypeptide.

The term "functionally equivalent", as utilized herein, refers to a protein capable of being recognized by an antibody specific to Mhp3, that is a protein capable of eliciting a substantially similar immunological response as the endogenous Mhp3 protein. Thus, an antibody raised against a functionally equivalent protein will also recognize Mhp3.

The term "immunogenicity" refers to the capability of a protein or polypeptide to elicit an immune response directed specifically against the protein or polypeptide.

The term "antigenicity" refers to the capability of a protein or polypeptide to be immunospecifically bound by an antibody to the protein or polypeptide.

The term "protection" or "protecting", as used herein with respect to a vaccine, means that the vaccine prevents or reduces the symptoms of the disease caused by the organism from which the antigen(s) used in the vaccine is derived.

The term "antibody", as used herein, refers to an immunoglobulin molecule able to bind to an antigen. Antibodies can be a polyclonal mixture or monoclonal. Antibodies can be intact immunoglobulins derived from natural sources or from recombinant sources and can be immunoreactive portions of intact immunoglobulins. Antibodies may exist in a variety of forms including, for example, Fv, Fab', F(ab')<sub>2</sub>, as well as in single chains. Single chain antibodies, in which genes for a heavy chain and a light chain are combined into a single coding sequence, may also be used.

The term "effective amount" refers to an amount of *mhp3* nucleotide or Mhp3 polypeptide sufficient to elicit an immune response in the subject to which it is administered. The immune response may comprise, without limitation, induction of cellular and/or humoral immunity.

The term "treating or preventing *M. hyopneumoniae* infection" means to inhibit the replication of *M. hyopneumoniae* bacteria, to inhibit *M. hyopneumoniae* transmission, or to prevent *M. hyopneumoniae* from establishing itself in its host, and to alleviate the symptoms of the disease caused by *M. hyopneumoniae* infection. The treatment is considered therapeutic if there is a reduction in bacterial load, decrease in pulmonary infections and/or increase in food uptake and/or growth.

The term "therapeutic agent" refers to any molecule, compound or treatment, preferably an antibacterial, that assists in the treatment of a bacterial infection or the diseases caused thereby.

As described herein, the inventor has discovered and characterized a *M. hyopneumoniae* gene encoding Mhp3, which is believed to be attached to the plasma membrane of *M. hyopneumoniae* by virtue of a lipid chain covalently attached to the protein. The invention provides recombinant means of expressing Mhp3 proteins that lack a signal sequence and the necessary signal for lipid modification, thus allowing for efficient and high yield expression of Mhp3 for use in vaccines against and treatments for diseases caused by infection with *M. hyopneumoniae*.

20 The invention further encompasses proteins having a sequence comprising at least 10, at least 20, at least 30, at least 40, at least 50 or at least 100 contiguous amino acids of SEQ ID NO:4 and nucleic acids encoding such proteins in the universal genetic code.

25 The invention further encompasses vaccine formulations comprising Mhp3 proteins. In certain embodiments, the vaccine formulations comprise isolated proteins selected from the group consisting of P46, P65, P97 and P102 and fragments, variants and derivatives thereof.

### NUCLEOTIDE SEQUENCES OF *mhp3*

The present invention encompasses nucleotide sequences of the *mhp3* gene and include those nucleotide sequences that encode species variants of Mhp3 as may be found in other *M. hyopneumoniae* species. A preferred embodiment of the invention encompasses the nucleotide sequences encoding an amino truncated form of the Mhp3 protein that is not modified by the covalent addition of fatty acid chains and is therefore not membrane localized.

In one mode of the preferred embodiment of the invention, the 5' deletion of *mhp3* corresponding to the amino terminal of Mhp3 encompasses the nucleotide sequences encoding amino acids 2-29 of Mhp3. In other modes of the embodiment, the 5' deletion of *mhp3* corresponds to the first 30, 31-32 or 33-40 amino acids.

5           The invention provides an isolated or purified DNA encoding in the mycoplasmal genetic code a protein having an amino acid sequence comprising least 10, at least 20, at least 30, at least 40, at least 50 or at least 100 contiguous amino acids of SEQ ID NO:2, or its complement. The invention also provides a DNA having a sequence comprising at least 90 contiguous nucleotides of SEQ ID NO:1, or its complement.

10           The invention further provides a DNA encoding in the universal genetic code a protein having an amino acid sequence comprising at least 10, at least 20, at least 30, at least 40, at least 50 or at least 100 contiguous amino acids of SEQ ID NO:4, or its complement. The invention further provides a DNA having the sequence of SEQ ID NO:3.

          The invention further provides an isolated DNA comprising a fragment of 15-40  
15   nucleotides, which fragment hybridizes under stringent conditions for PCR (as described below) to a DNA encoding in the mycoplasmal genetic code a protein having a sequence of at least 5 contiguous amino acids of SEQ ID NO:2, or its complement. In a preferred embodiment, the hybridization is specific to *M. hyopneumoniae*. As used herein, the term "hybridization specific to *M. hyopneumoniae*" indicates selective hybridization to the *M.*  
20   *hyopneumoniae* genome but not to genomes from related mycoplasmal species, such as *M. hyorhinis*, *M. flocculare*, *M. mycoides*, etc.

          The invention further provides an isolated DNA comprising a fragment of at least 90  
nucleotides, which fragment hybridizes under conditions of high stringency for filter  
hybridization (as described below) to a DNA encoding in the mycoplasmal genetic code a  
25   protein having a sequence of at least 30 contiguous amino acids of SEQ ID NO:2, or its complement.

          In a specific embodiment, a nucleic acid which is hybridizable to a *mhp3* nucleic acid  
(e.g., having a sequence as set forth in SEQ ID NO:1, SEQ ID NO:3 or SEQ ID NO:5), or to  
its complement, or to a nucleic acid encoding a *mhp3* derivative or analog, or to its  
30   complement, under conditions of low stringency is provided. By way of example and not  
limitation, procedures using such conditions of low stringency for regions of hybridization of  
over 90 nucleotides are as follows (see also Shilo and Weinberg, 1981, Proc. Natl. Acad. Sci.  
U.S.A. 78, 6789-6792). Filters containing DNA are pretreated for 6 h at 40°C in a solution  
containing 35% formamide, 5X SSC, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.1% PVP, 0.1%  
35   Ficoll, 1% BSA, and 500 µg/mL denatured salmon sperm DNA. Hybridizations are carried out  
in the same solution with the following modifications: 0.02% PVP, 0.02% Ficoll, 0.2% BSA,  
100 µg/mL salmon sperm DNA, 10% (wt/vol) dextran sulfate, and 5-20 X 10<sup>6</sup> cpm <sup>32</sup>P-labeled

probe is used. Filters are incubated in hybridization mixture for 18-20 h at 40°C, and then washed for 1.5 h at 55°C in a solution containing 2X SSC, 25 mM Tris-HCl (pH 7.4), 5 mM EDTA, and 0.1% SDS. The wash solution is replaced with fresh solution and incubated an additional 1.5 h at 60°C. Filters are blotted dry and exposed for autoradiography. If  
5 necessary, filters are washed for a third time at 65-68°C and re-exposed to film. Other conditions of low stringency which may be used are well known in the art (e.g., as employed for cross-species hybridizations).

In another specific embodiment, a nucleic acid which is hybridizable to a *mhp3* nucleic acid, or its complement, under conditions of high stringency is provided. By way of  
10 example and not limitation, procedures using such conditions of high stringency for regions of hybridization of over 90 nucleotides are as follows. Prehybridization of filters containing DNA is carried out for 8 h to overnight at 65°C in buffer composed of 6X SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 µg/mL denatured salmon sperm DNA. Filters are hybridized for 48 h at 65°C in prehybridization mixture  
15 containing 100 µg/mL denatured salmon sperm DNA and 5-20 X 10<sup>6</sup> cpm of <sup>32</sup>P-labeled probe. Washing of filters is done at 37°C for 1 h in a solution containing 2X SSC, 0.01% PVP, 0.01% Ficoll, and 0.01% BSA. This is followed by a wash in 0.1X SSC at 50°C for 45 min before autoradiography.

Other conditions of high stringency which may be used depend on the nature of the  
20 nucleic acid (e.g. length, GC content, etc.) and the purpose of the hybridization (detection, amplification, etc.) and are well known in the art. For example, stringent hybridization of an oligonucleotide of approximately 15-40 bases to a complementary sequence in the polymerase chain reaction (PCR) is done under the following conditions: a salt concentration of 50 mM KCl, a buffer concentration of 10 mM Tris-HCl, a Mg<sup>2+</sup> concentration of 1.5 mM, a  
25 pH of 7-7.5 and an annealing temperature of 55-60°C.

In another specific embodiment, a nucleic acid which is hybridizable to a *mhp3* nucleic acid, or its complement, under conditions of moderate stringency is provided. Selection of appropriate conditions for such stringencies is well known in the art (see e.g., Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, 2d Ed., Cold Spring Harbor  
30 Laboratory Press, Cold Spring Harbor, New York; see also, Ausubel et al., eds., in the Current Protocols in Molecular Biology series of laboratory technique manuals, © 1987-1997, Current Protocols, © 1994-1997 John Wiley and Sons, Inc.).

Nucleic acids encoding derivatives and analogs of *mhp3*-encoded proteins, and *mhp3* antisense nucleic acids are additionally provided. As is readily apparent, as used herein, a  
35 "nucleic acid encoding a fragment or portion of a *mhp3*-encoded protein" shall be construed as referring to a nucleic acid encoding only the recited fragment or portion of the *mhp3*-

encoded protein and not the other contiguous portions of the *mhp3*-encoded protein as a continuous sequence.

In a preferred specific embodiment, after hybridization, wash conditions are as follows. Each membrane is washed two times each for 30 minutes each at 45°C in 40 mM sodium phosphate, pH 7.2, 5% SDS, 1 mM EDTA, 0.5% bovine serum albumin, followed by four washes each for 30 minutes in sodium phosphate, pH 7.2, 1% SDS, 1 mM EDTA, and subsequently each membrane is treated differently as described below for low, medium, or high stringency hybridization conditions. For low stringency hybridization, membranes are not washed further. For medium stringency hybridization, membranes are additionally subjected to four washes each for 30 minutes in 40 mM sodium phosphate, pH 7.2, 1% SDS, 1 mM EDTA at 55°C. For high stringency hybridization, following the washes for low stringency, membranes are additionally subjected to four washes each for 30 minutes in 40 mM sodium phosphate, pH 7.2, 1% SDS, 1 mM EDTA at 55°C, followed by four washes each for 30 minutes in sodium phosphate, pH 7.2, 1% SDS, 1 mM EDTA at 65°C.

#### *mhp3*-ENCODED PROTEINS AND POLYPEPTIDES

The present invention provides recombinant Mhp3 proteins. In one embodiment, the protein has an amino acid sequence comprising at least 10, at least 20, at least 30, at least 40, at least 50 or at least 100 contiguous amino acids of SEQ ID NO:4 and is not covalently linked to a fatty acid moiety. In a further embodiment, the protein is an isolated protein. The present invention also provides compositions comprising such Mhp3 proteins. In certain specific embodiments, the compositions comprise an Mhp3 protein and a pharmaceutically acceptable carrier, or an Mhp3 protein and an adjuvant. In another specific embodiment, the composition comprises at least one other protein of *M. hyopneumoniae* such as, but not limited to, P46, P65, P97 or P102. In other embodiments, the composition comprises an Mhp3 protein and at least one other immunogenic or antigenic polypeptide which is not a *M. hyopneumoniae* polypeptide and is preferably a viral, bacterial or parasitic polypeptide. Such a composition is beneficial as a combination vaccine.

Further, the Mhp3 proteins of the present invention for use in vaccine preparations are substantially pure or homogenous. Methods which are well known to those skilled in the art can be used to determine protein purity or homogeneity, such as polyacrylamide gel electrophoresis of a sample, followed by visualizing a single polypeptide band on a staining gel. Higher resolution may be determined using HPLC or other similar methods well known in the art.

The present invention encompasses polypeptides which are typically purified from host cells expressing recombinant nucleotide sequences encoding these proteins. Such protein purification can be accomplished by a variety of methods well known in the art. In one embodiment, the Mhp3 protein of the present invention is expressed as a fusion protein, for



example with thioredoxin. The resulting recombinant fusion protein may be purified by affinity chromatography. In one mode of the embodiment, the Mhp3 protein is cleaved away from the heterologous moiety resulting in a substantially pure Mhp3 protein sample. Other methods may be used, see for example, the techniques described in "Methods In Enzymology", 1990, Academic Press, Inc., San Diego, "Protein Purification: Principles and practice", 1982, Springer-Verlag, New York.

#### EXPRESSION SYSTEMS

The present invention encompasses expression systems, both eukaryotic and prokaryotic expression vectors, which may be used to express both truncated and full-length forms of the *mhp3* protein.

In a preferred embodiment of the invention, the nucleic acid has the sequence of SEQ ID NO:3 and encodes a protein of SEQ ID NO:4, which includes residues 30-444 of SEQ ID NO:2. The TGA codons of *M. hyopneumoniae* have been changed to TGG codons.

A variety of host-expression vector systems may be utilized to express the antigenic protein sequences of the invention. Such host-expression systems represent vehicles by which the coding sequences of interest may be produced and subsequently purified, but also represent cells which may, when transformed or transfected with the appropriate nucleotide coding sequences, exhibit the *mhp3* gene products of the invention *in situ*. These include but are not limited to microorganisms such as bacteria (*e.g.*, *E. coli*, *B. subtilis*) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing *mhp3* coding sequences; yeast (*e.g.*, *Saccharomyces*, *Pichia*) transformed with recombinant yeast expression vectors containing the *mhp3* gene product coding sequences; insect cell systems infected with recombinant virus expression vectors (*e.g.*, baculovirus) containing the *mhp3* coding sequences; plant cell systems infected with recombinant virus expression vectors (*e.g.*, cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (*e.g.*, Ti plasmid) containing *mhp3* coding sequences; or mammalian cell systems (*e.g.*, COS, CHO, BHK, 293, 3T3) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (*e.g.*, metallothionein promoter) or from mammalian viruses (*e.g.*, the adenovirus late promoter; the vaccinia virus 7.5K promoter).

In a preferred embodiment, the expression system is a bacterial system. A number of expression vectors may be advantageously selected depending upon the use intended for the *mhp3* product being expressed. For example, when a large quantity of such a protein is to be produced, for the generation of pharmaceutical compositions of Mhp3 or for raising antibodies to Mhp3, for example, vectors which direct the expression of high levels of fusion protein products that are readily purified may be desirable. Preferably, the vectors contain promoters that direct inducible gene expression. Suitable vectors include, but are not limited,

to the *E. coli* expression vector pUR278 (Ruther et al., 1983, EMBO J. 2:1791), in which the *mhp3* coding sequences may be ligated individually into the vector in frame with the lac Z coding region so that a fusion protein is produced; pIN vectors (Inouye & Inouye, 1985, Nucleic Acids Res. 13:3101-3109; Van Heeke & Schuster, 1989, J. Biol. Chem. 264:5503-5509); pET vectors (Studier and Moffatt, 1986, J. Mol. Biol. 189:113; Rosenberg et al., 1987, Gene 56:125-135; the vectors are available from Novagen, Madison, Wisconsin), in which the *mhp3* coding sequence can be fused in frame to a sequence encoding multiple (e.g. six) histidine residues; pBAD vectors (Guzman et al., 1995, J. Bact. 177:4121-4130), using which Mhp3 can be expressed under the control of an arabinose inducible protein. pGEX vectors (Promega Corporation) may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. The pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety. The *mhp3* sequences can be cloned into a  $\lambda$  expression vector and expressed in  $\lambda^-$  bacterial strains. In a preferred mode of the embodiment, the bacterial strain is LW14, which contains a temperature sensitive  $\lambda$  repressor, such that protein expression from a  $\lambda$  vector is repressed at 30°C but active at 42°C. In a highly preferred embodiment, the vector Mhp3 is expressed as a thioredoxin fusion protein, which promotes the solubility of proteins that are normally insoluble. A thioredoxin-Mhp3 fusion protein is preferably expressed by ligating an Mhp3 coding sequence into the pBAD vector pBAD/Thio-TOPO (Invitrogen Corporation, Carlsbad, California). In a highly preferred mode of the embodiment, the thioredoxin-Mhp3 fusion protein is expressed in the *E. coli* strain BL21. Other vectors can be used and are known to those skilled in the art.

#### Mhp3 ANTIBODIES

According to the invention *mhp3*-encoded proteins and their derivatives and analogs may be used as an immunogens to generate antibodies which immunospecifically bind such an immunogen.

Various procedures known in the art may be used for the production of polyclonal antibodies to Mhp3. For the production of antibody, various host animals can be immunized by injection with the native Mhp3 protein, or a synthetic version, or derivative thereof, including but not limited to rabbits, mice, rats, etc. Various adjuvants may be used to increase the immunological response, depending on the host species (see, e.g. those used for the preparation of vaccines).

For preparation of monoclonal antibodies directed to a *mhp3*-encoded protein sequence or analog thereof, any technique which provides for the production of antibody molecules by continuous cell lines in culture may be used. For example, the hybridoma

technique originally developed by Kohler and Milstein, (Kohler and Milstein 1975, Nature 256:495-497), as well as the trioma technique, the human B-cell hybridoma technique (Kozbor et al., 1983, Immunology Today 4:72), and the EBV-hybridoma technique to produce human monoclonal antibodies (Cole et al., 1985, in *Monoclonal Antibodies and Cancer* 5 *Therapy*, Alan R. Liss, Inc., pp. 77-96). In an additional embodiment of the invention, monoclonal antibodies can be produced in germ-free animals utilizing recent technology (see e.g., PCT/US90/02545). According to the invention, human antibodies may be used and can be obtained by using human hybridomas (Cole et al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80:2026-2030) or by transforming human B cells with EBV virus *in vitro* (Cole et al., 1985, in 10 *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, pp. 77-96). In fact, according to the invention, techniques developed for the production of "chimeric antibodies" (Morrison et al., 1984, Proc. Natl. Acad. Sci. U.S.A. 81:6851-6855; Neuberger et al., 1984, Nature 312:604-608; Takeda et al., 1985, Nature 314:452-454) by splicing the genes from a mouse antibody molecule specific for a *mhp3*-encoded protein together with genes from a human 15 antibody molecule of appropriate biological activity can be used; such antibodies are within the scope of this invention.

According to the invention, techniques described for the production of single chain antibodies (U.S. Patent No. 4,946,778) can be adapted to produce *mhp3* gene product-specific single chain antibodies. An additional embodiment of the invention utilizes the 20 techniques described for the construction of Fab' expression libraries (Huse et al., 1989, Science 246:1275-1281) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity for *mhp3*-encoded proteins, derivatives, or analogs.

Antibody fragments which contain the idiotype of the molecule can be generated by known techniques. For example, such fragments include but are not limited to, the F(ab')<sub>2</sub> 25 fragment which can be produced by pepsin digestion of the antibody molecule, the Fab' fragments which can be generated by reducing the disulfide bridges of the F(ab')<sub>2</sub> fragment, the Fab fragments which can be generated by treating the antibody molecule with papain and a reducing agent, and Fv fragments.

In the production of antibodies, screening for the desired antibody can be 30 accomplished by techniques known in the art (e.g., enzyme-linked immunosorbent assay or ELISA). For example, to select antibodies which recognize a specific domain of a *mhp3*-encoded protein, one may assay generated hybridomas for a product which binds to a Mhp3 fragment containing such domain. For selection of an antibody that specifically binds a first Mhp3 homolog but which does not specifically bind a different Mhp3 homolog, one can select 35 on the basis of positive binding to the first Mhp3 homolog and a lack of binding to the second Mhp3 homolog.

The foregoing antibodies can be used in methods known in the art relating to the localization and activity of the *mhp3*-encoded protein sequences of the invention, e.g., measuring levels thereof in appropriate physiological samples, in diagnostic methods, immunotherapy, etc.

The invention further provides kits for the detection of *M. hyopneumoniae*. In one embodiment, the kit provides reagents for the detection of circulating antibodies against *M. hyopneumoniae* Mhp3 protein. In certain embodiments, the kits comprise a statement indicating that the kit is useful for diagnosis of *M. hyopneumoniae* infection. Minimally, the kit comprises in at least one container a protein having an amino acid sequence comprising at least 30 contiguous amino acids of SEQ ID NO:4. In one mode of the embodiment, the kit further comprises an anti-pig secondary antibody. In a preferred mode of the embodiment, the secondary antibody is conjugated to an enzyme that catalyzes a colorimetric reaction, such as alkaline phosphatase or horseradish peroxidase. In a further mode of the embodiment, the kit further comprises reagents for a colorimetric assay.

In another embodiment, the kit provides reagents for the detection of *M. hyopneumoniae* nucleic acids. In one mode of the embodiment, the kit provides reagents for the PCR detection of *M. hyopneumoniae* nucleic acids and comprises in at least one container a first isolated DNA comprising a fragment of at least 15 nucleotides, which fragment hybridizes under stringent conditions to a DNA encoding in the mycoplasmal genetic code a protein having a sequence of at least 5 contiguous amino acids of SEQ ID NO:2, and a second isolated DNA comprising a fragment of at least 15 nucleotides, which fragment hybridizes under stringent conditions to a DNA complementary to a DNA encoding in the mycoplasmal genetic code a protein having a sequence of at least 5 contiguous amino acids of SEQ ID NO:2. In another mode of the embodiment, the kit provides reagents for hybridization-based methods for the detection of the *M. hyopneumoniae* genome and comprises in at least one container an isolated DNA comprising a fragment of at least 15 nucleotides, which fragment hybridizes under stringent conditions to a DNA encoding in the mycoplasmal genetic code a protein having a sequence of at least 5 contiguous amino acids of SEQ ID NO:2, or the complement of said DNA, and wherein the hybridization is specific to *M. hyopneumoniae*. As used herein, the term "hybridization specific to *M. hyopneumoniae*" indicates selective hybridization to the *M. hyopneumoniae* genome but not to genomes from related mycoplasmal species, such as *M. hyorhinis*, *M. flocculare*, *M. mycoides*, etc.

## VACCINE FORMULATIONS AND METHODS OF ADMINISTRATION

Since the Mhp3 protein antigen of the present invention can be produced in large amounts, the antigen thus produced and purified has use in vaccine preparations. The Mhp3 protein also has utility in immunoassays, e.g., to detect or measure in a sample of body fluid from a vaccinated or potentially infected test animal the presence of antibodies to the antigen, and thus to monitor the immune response and/or to diagnose infection of the animal.

The preparation of vaccines containing an immunogenic polypeptide as the active ingredient is known to one skilled in the art.

#### DETERMINATION OF VACCINE EFFICACY

The immunopotency of the Mhp3 antigen can be determined by monitoring the immune response in test animals following immunization with the Mhp3 antigen, alone or in combination with at least one other polypeptide, or by use of any immunoassay known in the art. In a preferred embodiment, said other polypeptide is selected from the group consisting of *M. hyopneumoniae* P46, P65, P97 and P102 proteins. Generation of a humoral (antibody) response and/or cell-mediated immunity may be taken as an indication of an immune response.

Methods of introducing the vaccine may include oral, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal or any other standard routes of immunization. The immune response of the test subjects can be analyzed by various approaches such as: the reactivity of the resultant immune serum to the Mhp3 antigen, as assayed by known techniques, e.g., immunosorbant assay (ELISA), immunoblots, radioimmunoprecipitations, etc., or in the case where the Mhp3 antigen displays antigenicity or immunogenicity, by protection of the immunized host from infection by *M. hyopneumoniae* and/or attenuation of symptoms due to infection by *M. hyopneumoniae* in the immunized host.

#### VACCINE FORMULATIONS

The vaccines of the invention comprise recombinant Mhp3 and/or fragments, variants and derivatives thereof. In certain embodiments, the vaccines of the inventions comprise Mhp3 and at least one other antigenic *M. hyopneumoniae* polypeptide. Suitable antigenic polypeptides for use in combination with Mhp3 include but are not limited to the P46, P65, P97 and P102 proteins and/or fragments, variants and derivatives of said polypeptides. The non-Mhp3 polypeptides of the vaccines, such as the P46, P65, P97 and P102 proteins and their fragments, variants and derivatives, may be purified from *M. hyopneumoniae* cultures or recombinantly expressed.

Suitable preparations of such vaccines further include injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid prior to injection, may also be prepared. The preparation may also be emulsified. The active immunogenic ingredients are often mixed with adjuvants which are pharmaceutically acceptable and compatible with the active ingredient.

5           The effectiveness of an adjuvant may be determined by measuring the induction of antibodies directed against an immunogenic polypeptide containing a Mhp3 polypeptide epitope, the antibodies resulting from administration of this polypeptide in vaccines which are also comprised of the various adjuvants.

Many methods may be used to introduce the vaccine formulations of the invention; these include but are not limited to oral, intradermal, intramuscular, intraperitoneal, subcutaneous, intranasal routes, and via scarification (scratching through the top layers of skin, e.g., using a bifurcated needle).

The vaccine formulations of the invention comprise an effective immunizing amount of the Mhp3 protein and a pharmaceutically acceptable carrier. Vaccine preparations  
25 comprise an effective immunizing amount of one or more antigens and a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers are well known in the art and include but are not limited to saline, buffered saline, dextrose, water, glycerol, sterile isotonic aqueous buffer, and combinations thereof. One example of such an acceptable carrier is a physiologically balanced culture medium containing one or more stabilizing agents such as  
30 stabilized, hydrolyzed proteins, lactose, etc. The carrier is preferably sterile. The formulation should suit the mode of administration.

35            Use of purified antigens as vaccine preparations can be carried out by standard methods. For example, the purified protein(s) should be adjusted to an appropriate concentration, formulated with any suitable vaccine adjuvant and packaged for use. Suitable

adjuvants may include, but are not limited to: mineral gels, e.g., aluminum hydroxide; surface active substances such as lysolecithin; glycosides, e.g., saponin derivatives such as Quill A; pluronic polyols; polyanions; non-ionic block polymers, e.g., Pluronic F-127 (B.A.S.F., USA); peptides; mineral oils, e.g. Montanide ISA-50 (Seppic, Paris, France), oil emulsions, e.g. an emulsion of mineral oil such as BayolF/Arlacel A and water, or an emulsion of vegetable oil, water and an emulsifier such as lecithin; alum, and MDP. The immunogen may also be incorporated into liposomes, or conjugated to polysaccharides and/or other polymers for use in a vaccine formulation. In instances where the recombinant antigen is a hapten, i.e., a molecule that is antigenic in that it can react selectively with cognate antibodies, but not immunogenic in that it cannot elicit an immune response, the hapten may be covalently bound to a carrier or immunogenic molecule; for instance, a large protein such as serum albumin will confer immunogenicity to the hapten coupled to it. The hapten-carrier may be formulated for use as a vaccine.

Effective doses (immunizing amounts) of the vaccines of the invention may also be extrapolated from dose-response curves derived from model test systems.

The invention also provides a pharmaceutical pack or kit comprising one or more containers comprising one or more of the ingredients of the vaccine formulations of the invention.

The present invention thus provides a method of immunizing an animal, or treating or preventing various diseases or disorders in an animal, comprising administering to the animal an effective immunizing dose of a vaccine of the present invention.

#### USE OF ANTIBODIES GENERATED BY THE VACCINES OF THE INVENTION

The antibodies generated against the antigen by immunization with the Mhp3 proteins of the present invention also have potential uses in diagnostic immunoassays, passive immunotherapy, and generation of antiidiotypic antibodies.

The generated antibodies may be isolated by standard techniques known in the art (e.g., immunoaffinity chromatography, centrifugation, precipitation, etc.) and used in diagnostic immunoassays. The antibodies may also be used to monitor treatment and/or disease progression. Any immunoassay system known in the art, such as those listed *supra*, may be used for this purpose including but not limited to competitive and noncompetitive assay systems using techniques such as radioimmunoassays, ELISA (enzyme-linked immunosorbent assays), "sandwich" immunoassays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, protein A immunoassays and immunoelectrophoresis assays, to name but a few.

The vaccine formulations of the present invention can also be used to produce antibodies for use in passive immunotherapy, in which short-term protection of a host is

achieved by the administration of pre-formed antibody directed against a heterologous organism.

In immunization procedures, the amount of immunogen to be used and the immunization schedule will be determined by a physician skilled in the art and will be administered by reference to the immune response and antibody titers of the subject.

#### PACKAGING

The compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient. The pack may for example comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration. Compositions comprising a compound of the invention formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition.

#### EXAMPLES

##### Isolation of *M. hyopneumoniae* Chromosomal DNA

Genomic DNA from *M. hyopneumoniae* was isolated by the method of Dybvig and Alderete (Plasmid, 20:33-41; 1988), in which cells were harvested by centrifugation (10 min. at 6000g at 4°C), suspended in phosphate-buffered saline, and lysed by addition of 0.1 volume 10% sodium dodecyl sulfate. The lysate was extracted with a mixture of phenol, chloroform, and isoamyl alcohol (25:24:1) saturated with Tris-HCl. The aqueous phase was extracted with chloroform, and nucleic acids precipitated by the addition of 0.1 volume of 3M sodium acetate and 2 volumes of ice-cold ethanol. After incubation at -20°C for 1 hr, nucleic acids were recovered by centrifugation for 10 min in a microcentrifuge. Nucleic acids were resuspended in water containing 20 ug of RNase A/mL, and samples were stored at -20°C.

##### Molecular Cloning of *M. hyopneumoniae* mhp3

Degenerate oligonucleotide primers KWK40, KWK41, KWK42, KWK43, KWK42RC, and KWK43RC (SEQ ID NOs:10-15), were designed and synthesized (Genosys Biotechnologies, Inc.; The Woodlands, TX) based upon previously identified partial amino acid sequences (SEQ ID NOs:7-9) of Mhp3 (International patent publication WO 96/28472). The polymerase chain reaction (PCR) was carried out with various combinations of these primers in a 50uL reaction volume containing 1x PCR buffer (Perkin Elmer; Foster City, CA), 2.0 mM MgCl<sub>2</sub>, 1 μM each primer, 400 μM each deoxy-NTP, and 2.5 U AmpliTaq Gold (Perkin Elmer). Conditions for amplification consisted of denaturation at 94°C for 2 min, followed by 25 cycles of denaturation (94°C, 1 min), annealing (56°C, 1 min), and polymerization (72°C, 1 min). Using primers KWK41 (SEQ ID NO:11) and KWK42RC (SEQ ID NO:14), a fragment approximately 250 bp in length was amplified using 410 ng of *M. hyopneumoniae* strain 232 chromosomal DNA (passage n=5). The fragment was subcloned



into the TA cloning site of pCR2.1-TOPO (Invitrogen; Carlsbad, CA); the ligated product was transformed into *E. coli* TOP10 cells (Invitrogen). Cloning was confirmed by dideoxynucleotide chain termination sequencing (Advanced Genetic Analysis Center; St. Paul, MN) and restriction endonuclease digestion followed by agarose gel electrophoresis.

5           Inverse PCR, a method used to amplify sequences flanking a core region of DNA (Ochman, H., Medhora, M.M., Garza, D., and Hartl, D.L. 1990. In "PCR Protocols: A Guide to Methods and Applications." Academic Press, San Diego, CA) was used to clone the remaining 5' and 3' ends of the gene encoding Mhp3. Pools of *M. hyopneumoniae* strain 232 (passage n=5) chromosomal DNA fragments were generated by singly digesting uncut DNA  
10       with the following restriction endonucleases: *AluI*, *Bam*HI, *Eco*RV, *Eco*RI, *Hae*III, *Hinc*II, *Hind*III, *Nde*I, *Pvu*II, *Sau*3AI, *Spe*I, *Ssp*I, *Xba*I. Following digestion, the fragments were circularized by ligation and subjected to PCR using oligonucleotide primers RAC3 (SEQ ID NO:16) and RAC4 (SEQ ID NO:17), which were designed based upon sequence from the 250 bp fragment described above. Amplification with these primers was carried out as follows:  
15       denaturation at 94°C for 2 min, followed by 40 cycles of denaturation (94°C, 1 min), annealing (55°C, 1 min), and polymerization (72°C, 2 min). The *Ssp*I-digested chromosomal DNA pool yielded an approximate 600 bp fragment which was subcloned into pCR2.1-TOPO. Sequence analysis of the cloned fragment identified the 5' end of the gene. Oligonucleotides RAC7 (SEQ ID NO:18) and RAC8 (SEQ ID NO:19) were designed based upon this sequence  
20       in order to obtain further sequence corresponding to the 3' end of *mhp3*. Conditions for amplification with these primers consisted of denaturation at 94°C for 9 min, followed by 40 cycles of denaturation (94°C, 30 sec), annealing (50°C, 30 sec), and polymerization (72°C, 1 min). When the *Spe*I-digested DNA pool was used as template, multiple products (250 bp to >1 kb) were amplified; the mixture of fragments was cloned into pCR2.1-TOPO. Sequence  
25       analysis of the largest fragment cloned (~1.2kb) provided additional 3' sequence data. From this data, oligonucleotides RAC12 (SEQ ID NO:20) and RAC15 (SEQ ID NO:23) were designed and synthesized to be used for PCR amplification using the *Hind*III-digested DNA pool as template. Parameters consisted of denaturation at 94°C for 9 min, followed by 40 cycles of denaturation (94°C, 30 sec), annealing (55°C, 30 sec), and polymerization (72°C, 2  
30       min), plus a final polymerization step at 72°C for 7 min. A fragment approximately 600 bp in length was amplified, cloned into pCR2.1-TOPO, and sequenced. Data obtained provided additional 3' sequence within the gene encoding Mhp3. Further PCR amplification with RAC12 (SEQ ID NO:20) and RAC15 (SEQ ID NO:23) was carried out using the *Hinc*II-digested DNA pool as template. Conditions for amplification were denaturation at 94°C for 9  
35       min, followed by 35 cycles of denaturation (94°C, 1 min), annealing (55°C, 1 min), and polymerization (72°C, 3 min), plus a final polymerization step (72°C, 7 min). An approximate 700 bp fragment was amplified and cloned into pCR2.1-TOPO. Sequencing of the cloned

fragment generated new 3' sequence data, including that which encoded the carboxyl terminus of the polypeptide.

Results from the preliminary sequencing described above were used to design oligonucleotide primers for the specific amplification of the *mhp3* gene directly from low-  
5 passage (n=4) *M. hyopneumoniae* strain 232 chromosomal DNA. These products were sequenced directly in an attempt to avoid the introduction of sequence artifacts due to possible mutations which may arise during PCR amplification and subsequent cloning steps.

Synthetic oligonucleotides which flank the *mhp3* gene were used to specifically amplify the open reading frame (ORF) from chromosomal DNA. PCR amplifications were  
10 carried out in triplicate and contained 1 µM each primer Mhp3-U1 (SEQ ID NO:31) and Mhp3-D (SEQ ID NO:33), 360 ng purified chromosomal DNA, 1x PC2 buffer (Ab Peptides, Inc; St. Louis, MO), 200 µM each dNTP, 7.5 U KlenTaq1 (Ab Peptides, Inc) and 0.15 U cloned *Pfu* (Stratagene; La Jolla, CA) thermostable polymerase in a 50 µL final sample volume. Conditions for amplification consisted of denaturation at 94°C for 5 min, followed by 25 cycles  
15 of denaturation (94°C, 30 sec), annealing (55°C, 30 sec), and polymerization (72°C; 3 min, 45 sec), plus a final extension at 72°C for 7 min. Following amplification, the triplicate sample was pooled and the specific product was purified by extraction with spin chromatography (QIAquick™ PCR purification kit, Qiagen; Santa Clarita, CA). The pooled mixture was then subjected to direct sequence analysis using DyeDeoxy termination reactions on an ABI  
20 automated DNA sequencer (Lark Technologies Inc., Houston, TX).

Synthetic oligonucleotide primers (SEQ ID NOs:16-28, 31, and 33) were used to sequence both DNA strands of the amplified products from *M. hyopneumoniae* strain 232. The nucleotide sequence of the *mhp3* gene and deduced Mhp3 protein encoded within this region is presented in SEQ ID NO:1 and Seq ID No 2, respectively.

The *mhp3* ORF extends from nucleotides 97-1452 of SEQ ID NO:1, and encodes a  
25 451 amino acid protein (SEQ ID NO: 2) having a theoretical molecular weight of 49,775 daltons. The encoded polypeptide would contain 8 tryptophan residues, 7 which are encoded by the TGA codon (UGA in mRNA), known to specify for the addition of this amino acid in many mycoplasma spp. (Dybvig, K., 1990. Ann. Rev. Microbiol. 44:81-104; Yamao, F., Muto, A., Kawauchi, Y., 1985, Proc. Natl. Acad. Sci. U.S.A. 82:2306-2309). The amino terminus of the encoded protein appears to have properties characteristic of a prokaryotic signal sequence (von Heijne, G., 1985. J. Mol. Biol. 184: 99-105; Nielsen, H., Engelbrecht, J., Brunak, S., and von Heijne, G., 1997. Protein Engineering, 10: 1-6), although the precise site of cleavage is not presently known. The cysteine residue at position 29 of the encoded  
30 protein (SEQ ID NO: 2) is believed to be modified following processing by the addition of a sulfhydryl-linked fatty acid to make Mhp3 a lipoprotein (Razin, S., Yogev, D., and Naot, Y. 1998. Microbiol. Mol. Biol. Rev. 62:1094-1156).

15

20

25

## 35

Collection (ATCC). The pooled mixture resulting from triplicate PCR reactions employing

specific 5' and 3' primers Mhp3-U1 (SEQ ID NO:31) and Mhp3-D (SEQ ID NO:33) as described *supra* was isolated by extraction with spin chromatography (QIAquick™) and inserted into the TA cloning site of pCR2.1-TOPO. Single sequence extension reactions utilizing vector-specific sequencing primers confirmed the endpoints of the amplified 1,692  
5 base pair fragment, and revealed that the gene encoding Mhp3 was in the opposite orientation relative to the lactose promoter. This plasmid construct was designated pER427 and introduced into *E. coli* TOP10 cells (Invitrogen, Carlsbad, CA). The resulting strain was designated Pz427.

#### Site-Directed Mutagenesis of the mhp3 Gene

10 The preparation of DNA encoding Mhp3 for expression in *E. coli* required modifying the *M. hyopneumoniae* *mhp3* gene by removal of the sequence that encodes the presumed leader and the fatty acid attachment site, cysteine 29, and the conversion of 6 TGA codons to TGG codons. The oligonucleotide primers used for the amplification of the gene lacking the sequence encoding for the signal peptide were designated RAC 23 (SEQ ID NO:29) and RAC  
15 24 (SEQ ID NO:30). The conditions for amplification of that fragment from *M. hyopneumoniae* strain 232 (passage n=5) chromosomal DNA were denaturation at 94°C for 9 min, followed by 25 cycles of denaturation (94°C, 1 min), annealing (50°C, 1 min), and polymerization (72°C, 2min), plus a final polymerization step (72°C, 7 min). The amplified fragment was cloned into pCR2.1-TOPO; confirmation of cloning was by sequencing and restriction endonuclease  
20 digestion followed by gel electrophoresis. The sequence at the 5' end of the cloned fragment encodes for the initiating methionine residue, then a tryptophan residue, which is the amino acid following the cysteine residue at position 29 of the encoded polypeptide (see SEQ ID NO:2). At the 3' end, base changes were introduced into the wild-type nucleotide sequence (SEQ ID NO:1) which created a restriction site for cloning purposes. This resulted in the  
25 carboxy-terminal 2 amino acids of the wild-type polypeptide, Lys-Asn (SEQ ID NO:2) being replaced by the sequence Asn-Leu (Xaa-Xaa in SEQ ID NO:4). An additional T nucleotide was present in the RAC 24 primer (SEQ ID NO:30) compared to the wild type gene, but was not present in the PCR product. Oligonucleotides RAC 23 (SEQ ID NO:29) and RAC 24 (SEQ ID NO:30) contained synthetic restrictions sites *Nde*I and *Xba*I, respectively, near their  
30 5' ends to facilitate the cloning of the gene into various plasmids. Additional nucleotides (6 for RAC 23 (SEQ ID NO:29); 7 for RAC 24 (SEQ ID NO:30)) were also added at the 5' end of each primer to facilitate cutting by the respective restriction enzymes.

Once the sequence encoding for the signal peptide was removed, six internal TGA codons remained in the gene. To enable expression of the full-length polypeptide in *E. coli*,  
35 these were converted to TGG codons by oligonucleotide-directed *in vitro* mutagenesis. Plasmid pCR2.1-TOPO:*mhp3* was transformed into *E. coli* strain CJ236 (*dif*ung). The addition of helper phage R408 to cells containing the plasmid led to the production of phage

particles having uracil-containing single-stranded (ss) DNA. These particles were isolated, and ssDNA was purified by extraction and precipitation. Mutagenesis was carried out using this DNA as template, oligonucleotides Mhp3-2M, Mhp3-3M, Mhp3-4M, Mhp3-5M, Mhp3-6M, Mhp3-7M (SEQ ID NOs:35-40), and reagents from the MutaGene System (BioRad Laboratories; Hercules, CA). The ssDNA, oligonucleotides and annealing buffer were mixed and heated to 70°C, then allowed to cool to 30°C over a 1 hr period. Synthesis of the complementary strand was performed by adding T4 DNA ligase, T7 DNA polymerase, and synthesis buffer. The mixture was incubated on ice for 5 min, then room temperature for 5 min, followed by 37°C for 30 min. The resulting double-stranded DNA molecules were transformed into DH5α UltraComp cells (Gibco BRL; Gaithersburg, MD). Clones were propagated and screened for the desired mutations by sequencing. All mutations (TGA>TGG) were confirmed in this manner. In addition, an A>G transition inadvertently occurred corresponding to nucleotide 388 of the wild-type gene (SEQ ID NO:1) by virtue of the sequence of oligonucleotide Mhp3-2M (SEQ ID NO:35). This resulted in alteration of the encoded residue from serine(AGT) at amino acid residue 98 of wild-type Mhp3 (SEQ ID NO:2) to glycine (GGT) at amino acid residue 70 of recombinant Mhp3 (SEQ ID NO:4).

The recombinant *mhp3* gene (with or without the inadvertent A>G transition described *supra*) that resulted from the above changes is depicted in SEQ ID NO:3, and the open reading frame encoded by the recombinant *mhp3* gene (with glycine at amino acid residue 70) is depicted in SEQ ID NO:4.

#### Cloning of Recombinant *mhp3* Gene into Expression Vector and Expression Host

##### Strain

For the purpose of recombinant protein expression, the mutated *mhp3* gene lacking the sequence encoding the signal peptide (SEQ ID NO:3) was cloned into the pBAD/Thio-TOPO expression plasmid (Invitrogen); this construct was directly transformed into the expression host *E. coli* BL21. A clone was identified which contained the appropriate plasmid.

##### Expression of Recombinant Mhp3 Protein

Frozen working stock of the *E. coli* BL21 transformant expressing the thioredoxin-Mhp3 fusion was thawed and seeded at a 1:5000 dilution into RWLDM/D vi defined medium, which contains the following: K<sub>2</sub>HPO<sub>4</sub> (6 g/L), KH<sub>2</sub>PO<sub>4</sub> (3 g/L), (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub> (5 g/L), NaCl (2 g/L), 0.2 mL CaCl<sub>2</sub> (15 g/L), 0.4 mL FeCl<sub>3</sub>·6H<sub>2</sub>O (5 g/L), 0.4 mL MgSO<sub>4</sub>·7H<sub>2</sub>O (480 g/L), ZnCl<sub>2</sub> (6.5 g/L), MnSO<sub>4</sub>·H<sub>2</sub>O (12 g/L), Na<sub>2</sub>MoO<sub>4</sub>·2H<sub>2</sub>O (5 g/L), CuSO<sub>4</sub> (1.5 g/L), CoCl<sub>2</sub>·6H<sub>2</sub>O (2 g/L), H<sub>3</sub>BO<sub>3</sub> (0.5 g/L), and 37% HCl (5ml/L). Carbenicillin was also added to a concentration of 125 µg/mL. The culture was grown under fed-batch conditions (50% dextrose) in a 5 liter working volume BioFlow 3000 fermentor (New Brunswick Scientific; Edison, NJ) at 37°C until A<sub>625</sub> was 10-20.

Wet cells of the *E. coli* BL21 transformant expressing recombinant thioredoxin-Mhp3 from the 5 liter fermentation were harvested by centrifugation and re-suspended in phosphate-buffered saline. The cells were mechanically lysed. Following centrifugation, the pellet was discarded. The supernatant was passed over an ion exchange column, and eluted off using a NaCl gradient. Fractions containing the fusion protein were pooled, dialyzed to remove the NaCl, and filter-sterilized using a 0.2 µm filter. This preparation is used for the vaccination trials.

#### Immunological Characterization of Recombinant Mhp3

The protein concentration of the recombinant thioredoxin-Mhp3 prepared as described above was determined using a BCA Protein Assay kit (Pierce). In brief, each sample was diluted 1/10, 1/20, 1/40, and 1/80 in sterile deionized, distilled water (ddH<sub>2</sub>O). BSA (protein standard) was diluted to concentrations ranging from 200 to 800 µg/mL. A 20 µL volume of sample or standard was added to triplicate wells in a 96 well microtiter plate, and 200µL of Reagent B diluted 1/50 in Reagent A was added to each well. The plate was incubated at 37°C for 30 min. Sample absorbance was determined at 560 nm. The protein concentration for each sample was calculated by extrapolation using the BSA standard curve.

Aliquots of recombinant Mhp3 (protein load was variable) and whole bacterial cell lysates of *M. hyopneumoniae*, *Mycoplasma hyorhinis*, and *Mycoplasma mycoides* subspecies *mycoides* were resuspended to a final volume of 10 µL, and 10 µL of 2x reducing sample buffer (Owl Scientific) was added. Samples were heated for 10 min. at 100°C, and the entire volume was loaded into separate wells of a 10-well, 1.5 mm thick, 10% Tris-glycine gel (Novex). Unstained, broad-range molecular weight markers (Novex) were also included.

Proteins separated by SDS-PAGE were transferred to PVDF membrane (Owl Scientific) at 100 mA constant current for 1 hr. The blot was incubated in blocking buffer consisting of 5% skim milk powder and 0.5% Tween 20 in TBS (TBST) for 1 hr at room temperature with gentle agitation. The blocking buffer was removed, and the membrane was washed 1 time for 5 min with TBST. The primary antibody was obtained from a pig following experimental challenge with *M. hyopneumoniae* strain 232. Diluted serum was added to the membrane, followed by a 1 hr incubation at room temperature. Alkaline phosphatase-conjugated Protein G antibody (Pierce) was diluted, added to the washed membrane, and incubated for 1 hr at room temperature. The membrane was washed with TBST, and the substrate BCIP/NBT (Kirkegaard and Perry Laboratories) was added to the membrane and incubated until a suitable color reaction developed. The membrane was then rinsed with water to stop the reaction, and dried at room temperature.

Serum from the pig experimentally challenged with *M. hyopneumoniae* did recognize the purified recombinantly-expressed Mhp3 (FIG. 2), as a band of 60kDa was identified. This suggests that the recombinant protein expressed epitopes which were recognized by

antibodies generated in response to exposure of the pig to whole-cell *M. hyopneumoniae* organisms.

Animal Study to Test Efficacy of Recombinant Mhp3 as a Vaccine Candidate

5 Healthy crossbred pigs (approximately 12 to 16 days of age) without a history of previous vaccination against *M. hyopneumoniae* or disease caused by *M. hyopneumoniae* are obtained. Animals are randomly assigned by litter into groups. Pigs are allowed to acclimate for a minimum of five days prior to the initiation of the study.

10 Animals are vaccinated with 1 mL of the appropriate experimental vaccine by the intramuscular route (IM; left neck muscle) on day "0" when pigs are approximately 19 to 23 days of age. At approximately two to three weeks following first vaccination pigs receive a second 1 mL dose (IM; right neck muscle) of the appropriate experimental vaccine. All pigs are closely observed (for up to 1 hour or as warranted) for any post-vaccinal signs such as vomiting, depression, diarrhea, ataxia-incoordination, increased respiration, or trembling.

15 At approximately two to four weeks following the second vaccination, pigs are challenged intranasally with 1 mL/nare of a live virulent lung homogenate culture of *M. hyopneumoniae* strain 232 containing approximately  $5.0 \times 10^8$  color changing units/mL (CCU/mL).

20 All challenged animals are necropsied at approximately 4 weeks following challenge. Lungs are removed and evaluated grossly for characteristic lesions attributable to a *M. hyopneumoniae* infection. Individual lung lesion scores will be determined by image analysis. A bias sample of lung tissue may be obtained from each challenged animal for bacterial isolation (CCU/g of tissue), histopathology, and IFA.

DEPOSIT OF MICROORGANISMS

25 The following microorganism strain was deposited with the American Type Culture Collection (ATCC), 10801 University Blvd., Manassas, VA on September 9, 1999 and has been assigned the accession number indicated below.

Microorganism

Pz427

Accession Number

PTA-634

30 The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawing. Such modifications are intended to fall within the scope of the appended claims.

	0	0.0001	0.0002	0.0003	0.0004	0.0005	0.0006	0.0007	0.0008	0.0009	0.001	0.0011	0.0012	0.0013	0.0014	0.0015	0.0016	0.0017	0.0018	0.0019	0.002	0.0021	0.0022	0.0023	0.0024	0.0025	0.0026	0.0027	0.0028	0.0029	0.003	0.0031	0.0032	0.0033	0.0034	0.0035	0.0036	0.0037	0.0038	0.0039	0.004	0.0041	0.0042	0.0043	0.0044	0.0045	0.0046	0.0047	0.0048	0.0049	0.005	0.0051	0.0052	0.0053	0.0054	0.0055	0.0056	0.0057	0.0058	0.0059	0.006	0.0061	0.0062	0.0063	0.0064	0.0065	0.0066	0.0067	0.0068	0.0069	0.007	0.0071	0.0072	0.0073	0.0074	0.0075	0.0076	0.0077	0.0078	0.0079	0.008	0.0081	0.0082	0.0083	0.0084	0.0085	0.0086	0.0087	0.0088	0.0089	0.009	0.0091	0.0092	0.0093	0.0094	0.0095	0.0096	0.0097	0.0098	0.0099	0.01	0.0101	0.0102	0.0103	0.0104	0.0105	0.0106	0.0107	0.0108	0.0109	0.011	0.0111	0.0112	0.0113	0.0114	0.0115	0.0116	0.0117	0.0118	0.0119	0.012	0.0121	0.0122	0.0123	0.0124	0.0125	0.0126	0.0127	0.0128	0.0129	0.013	0.0131	0.0132	0.0133	0.0134	0.0135	0.0136	0.0137	0.0138	0.0139	0.014	0.0141	0.0142	0.0143	0.0144	0.0145	0.0146	0.0147	0.0148	0.0149	0.015	0.0151	0.0152	0.0153	0.0154	0.0155	0.0156	0.0157	0.0158	0.0159	0.016	0.0161	0.0162	0.0163	0.0164	0.0165	0.0166	0.0167	0.0168	0.0169	0.017	0.0171	0.0172	0.0173	0.0174	0.0175	0.0176	0.0177	0.0178	0.0179	0.018	0.0181	0.0182	0.0183	0.0184	0.0185	0.0186	0.0187	0.0188	0.0189	0.019	0.0191	0.0192	0.0193	0.0194	0.0195	0.0196	0.0197	0.0198	0.0199	0.02	0.0201	0.0202	0.0203	0.0204	0.0205	0.0206	0.0207	0.0208	0.0209	0.021	0.0211	0.0212	0.0213	0.0214	0.0215	0.0216	0.0217	0.0218	0.0219	0.022	0.0221	0.0222	0.0223	0.0224	0.0225	0.0226	0.0227	0.0228	0.0229	0.023	0.0231	0.0232	0.0233	0.0234	0.0235	0.0236	0.0237	0.0238	0.0239	0.024	0.0241	0.0242	0.0243	0.0244	0.0245	0.0246	0.0247	0.0248	0.0249	0.025	0.0251	0.0252	0.0253	0.0254	0.0255	0.0256	0.0257	0.0258	0.0259	0.026	0.0261	0.0262	0.0263	0.0264	0.0265	0.0266	0.0267	0.0268	0.0269	0.027	0.0271	0.0272	0.0273	0.0274	0.0275	0.0276	0.0277	0.0278	0.0279	0.028	0.0281	0.0282	0.0283	0.0284	0.0285	0.0286	0.0287	0.0288	0.0289	0.029	0.0291	0.0292	0.0293	0.0294	0.0295	0.0296	0.0297	0.0298	0.0299	0.03	0.0301	0.0302	0.0303	0.0304	0.0305	0.0306	0.0307	0.0308	0.0309	0.031	0.0311	0.0312	0.0313	0.0314	0.0315	0.0316	0.0317	0.0318	0.0319	0.032	0.0321	0.0322	0.0323	0.0324	0.0325	0.0326	0.0327	0.0328	0.0329	0.033	0.0331	0.0332	0.0333	0.0334	0.0335	0.0336	0.0337	0.0338	0.0339	0.034	0.0341	0.0342	0.0343	0.0344	0.0345	0.0346	0.0347	0.0348	0.0349	0.035	0.0351	0.0352	0.0353	0.0354	0.0355	0.0356	0.0357	0.0358	0.0359	0.036	0.0361	0.0362	0.0363	0.0364	0.0365	0.0366	0.0367	0.0368	0.0369	0.037	0.0371	0.0372	0.0373	0.0374
--	---	--------	--------	--------	--------	--------	--------	--------	--------	--------	-------	--------	--------	--------	--------	--------	--------	--------	--------	--------	-------	--------	--------	--------	--------	--------	--------	--------	--------	--------	-------	--------	--------	--------	--------	--------	--------	--------	--------	--------	-------	--------	--------	--------	--------	--------	--------	--------	--------	--------	-------	--------	--------	--------	--------	--------	--------	--------	--------	--------	-------	--------	--------	--------	--------	--------	--------	--------	--------	--------	-------	--------	--------	--------	--------	--------	--------	--------	--------	--------	-------	--------	--------	--------	--------	--------	--------	--------	--------	--------	-------	--------	--------	--------	--------	--------	--------	--------	--------	--------	------	--------	--------	--------	--------	--------	--------	--------	--------	--------	-------	--------	--------	--------	--------	--------	--------	--------	--------	--------	-------	--------	--------	--------	--------	--------	--------	--------	--------	--------	-------	--------	--------	--------	--------	--------	--------	--------	--------	--------	-------	--------	--------	--------	--------	--------	--------	--------	--------	--------	-------	--------	--------	--------	--------	--------	--------	--------	--------	--------	-------	--------	--------	--------	--------	--------	--------	--------	--------	--------	-------	--------	--------	--------	--------	--------	--------	--------	--------	--------	-------	--------	--------	--------	--------	--------	--------	--------	--------	--------	-------	--------	--------	--------	--------	--------	--------	--------	--------	--------	------	--------	--------	--------	--------	--------	--------	--------	--------	--------	-------	--------	--------	--------	--------	--------	--------	--------	--------	--------	-------	--------	--------	--------	--------	--------	--------	--------	--------	--------	-------	--------	--------	--------	--------	--------	--------	--------	--------	--------	-------	--------	--------	--------	--------	--------	--------	--------	--------	--------	-------	--------	--------	--------	--------	--------	--------	--------	--------	--------	-------	--------	--------	--------	--------	--------	--------	--------	--------	--------	-------	--------	--------	--------	--------	--------	--------	--------	--------	--------	-------	--------	--------	--------	--------	--------	--------	--------	--------	--------	-------	--------	--------	--------	--------	--------	--------	--------	--------	--------	------	--------	--------	--------	--------	--------	--------	--------	--------	--------	-------	--------	--------	--------	--------	--------	--------	--------	--------	--------	-------	--------	--------	--------	--------	--------	--------	--------	--------	--------	-------	--------	--------	--------	--------	--------	--------	--------	--------	--------	-------	--------	--------	--------	--------	--------	--------	--------	--------	--------	-------	--------	--------	--------	--------	--------	--------	--------	--------	--------	-------	--------	--------	--------	--------	--------	--------	--------	--------	--------	-------	--------	--------	--------	--------



CLAIMS

What is claimed is:

1. A protein having an amino acid sequence comprising at least 30 contiguous amino acids of SEQ ID NO:4, wherein said protein does not have a fatty acid acylated cysteine followed by the amino acid sequence Trp Asp Lys Glu, and does not have a C-terminal homoserine lactone.
2. The protein of claim 1 having an amino acid sequence comprising at least 50 contiguous amino acids of SEQ ID NO:4.
3. A protein having an amino acid sequence comprising at least amino acids 1-30 of SEQ ID NO:4.
4. The protein of claim 3 having an amino acid sequence comprising SEQ ID NO:4.
5. The protein of claim 1 which is an isolated protein.
6. The protein of claim 1 which is a fusion protein.
7. The protein of claim 6, in which the fusion protein is a thioredoxin fusion protein.
8. A composition comprising the protein of claim 1 and a pharmaceutically acceptable carrier.
9. The composition of claim 8, further comprising an adjuvant.
10. The composition of claim 8, further comprising at least one polypeptide selected from the group consisting of *Mycoplasma hyopneumoniae* P46, P65, P97 and P102.
11. An immunogenic protein having an amino acid sequence as depicted in SEQ ID NO:2, or a fragment, variant or derivative thereof, wherein the immunogenic protein does not have a fatty acid acylated cysteine followed by the amino acid sequence Trp Asp Lys Glu, and does not have a C-terminal homoserine lactone.
12. An immunogenic protein having an amino acid sequence as depicted in SEQ ID NO:4, or a fragment, variant or derivative thereof, wherein the immunogenic protein

EXPRESS MAIL # EJ62133038345

does not have a fatty acid acylated cysteine followed by the amino acid sequence Trp Asp Lys Glu, and does not have a C-terminal homoserine lactone.

13. A method of treating or preventing a disease or disorder in an animal caused by infection with *Mycoplasma hyopneumoniae* comprising administering to the animal a vaccine formulation comprising (i) a protein having an amino acid sequence comprising at least 30 contiguous amino acids of SEQ ID NO:4, wherein said protein does not have a fatty acid acylated cysteine followed by the amino acid sequence Trp Asp Lys Glu, and (ii) a pharmaceutically acceptable carrier, in an amount sufficient to elicit an increase in *Mycoplasma hyopneumoniae* specific cellular or humoral responses.
14. The method of claim 13, wherein said protein has an amino acid sequence comprising at least 50 contiguous amino acids of SEQ ID NO:4.
15. A method of treating or preventing a disease or disorder in an animal caused by infection with *Mycoplasma hyopneumoniae* comprising administering to the animal a vaccine formulation comprising (i) an antigenic or immunogenic protein having an amino acid sequence comprising at least amino acids 1-30 of SEQ ID NO:4, and (ii) a pharmaceutically acceptable carrier, in an amount sufficient to elicit an increase in *Mycoplasma hyopneumoniae* specific cellular or humoral responses.
16. The method of claim 15, wherein said protein has an amino acid sequence comprising SEQ ID NO:4.
17. The method of claim 13, wherein said animal is a pig.
18. An isolated or purified DNA encoding in the mycoplasmal genetic code a protein having an amino acid sequence comprising at least 30 contiguous amino acids of SEQ ID NO:2, or its complement.
19. The DNA of claim 18, wherein the protein has a sequence comprising at least 50 contiguous amino acids of SEQ ID NO:2.
20. The DNA of claim 18, wherein the DNA has a sequence comprising at least 90 contiguous nucleotides of SEQ ID NO:1.

21. A DNA encoding in the universal genetic code a protein having an amino acid sequence comprising at least 30 contiguous amino acids of SEQ ID NO:4, or its complement.
- 5 22. The DNA of claim 21, wherein the protein has a sequence comprising at least 50 contiguous amino acids of SEQ ID NO:4.
23. The DNA of claim 21, wherein the DNA has a sequence comprising at least 90 contiguous nucleotides of SEQ ID NO:3.
- 10 24. The DNA of claim 22 operably linked to a heterologous promoter.
25. The DNA of claim 24 which further comprises an origin of replication active in a prokaryotic cell.
- 15 26. The DNA of claim 24 which further comprises an origin of replication active in a eukaryotic cell.
27. A host cell comprising the isolated DNA of claim 24.
- 20 28. The host cell of claim 27, wherein said cell is *E. coli* BL21 and said DNA is the expression vector pBAD/Thio-TOPO.
- 25 29. A method for the production of apo-Mhp3 or a fragment thereof, said method comprising (i) growing the cells of claim 27 under conditions wherein apo-Mhp3 is expressed, and (ii) recovering said protein.
30. The method of claim 29, wherein said protein is recovered in a soluble form.
- 30 31. The method of claim 29, wherein said protein is recovered in an insoluble form.
- 35 32. A method of treating or preventing a disease or disorder in an animal caused by infection with *Mycoplasma hyopneumoniae* comprising administering to the animal a vaccine formulation comprising (i) the DNA of claim 20, and (ii) a pharmaceutically acceptable carrier, in an amount sufficient to elicit an increase in *Mycoplasma hyopneumoniae* specific cellular or humoral responses.

33. The method of claim 32 wherein said animal is a pig.
34. An isolated DNA comprising a fragment of 15-40 nucleotides, which fragment hybridizes under stringent conditions for PCR to a DNA encoding in the mycoplasmal genetic code a protein having a sequence of at least 5 contiguous amino acids of SEQ ID NO:2, or its complement.
35. The isolated DNA of claim 34, wherein the hybridization is specific to *M. hyopneumoniae*.
36. An isolated DNA comprising a fragment of at least 90 nucleotides, which fragment hybridizes under conditions of high stringency for filter hybridization to a DNA encoding in the mycoplasmal genetic code a protein having a sequence of at least 30 contiguous amino acids of SEQ ID NO:2, or its complement.
37. A kit comprising in at least one container a first isolated DNA comprising a fragment of at least 15 nucleotides, which fragment hybridizes under stringent conditions for PCR to a DNA encoding in the mycoplasmal genetic code a protein having a sequence of at least 5 contiguous amino acids of SEQ ID NO:2, and a second isolated DNA comprising a fragment of at least 15 nucleotides, which fragment hybridizes under stringent conditions for PCR to a DNA complementary to a DNA encoding in the mycoplasmal genetic code a protein having a sequence of at least 5 contiguous amino acids of SEQ ID NO:2, wherein said kit comprises a statement indicating that the kit is useful for diagnosis of *M. hyopneumoniae* infection.
38. The kit of claim 37, wherein the hybridization is specific to *M. hyopneumoniae*.
39. A kit comprising in at least one container the isolated DNA of claim 34, wherein the hybridization is specific to *M. hyopneumoniae* and wherein said kit comprises a statement indicating that the kit is useful for diagnosis of *M. hyopneumoniae* infection.
40. A kit comprising in at least one container a protein having an amino acid sequence comprising at least 30 contiguous amino acids of SEQ ID NO:4 and a statement indicating that the kit is useful for diagnosis of *M. hyopneumoniae* infection.
41. The kit of claim 40, further comprising an anti-pig secondary antibody.

42. The kit of claim 41, in which the secondary antibody is conjugated to an enzyme that catalyzes a colorimetric reaction.
- 5 43. The kit of claim 42, wherein the enzyme is selected from the group consisting of alkaline phosphatase and horseradish peroxidase.
44. The kit of claim 42, further comprising reagents for a colorimetric assay.


## mhp3 GENE AND USES THEREOF

The present invention relates to *mhp3* nucleic acids and proteins encoded by the foregoing. The present invention further relates to novel apoprotein antigens encoded by *mhp3* for use in vaccines to prevent and treat diseases caused by infection with *Mycoplasma hyopneumoniae*. The invention further relates to methods for the recombinant production of such antigens.

**FIG. 1**

Mhp3	Ag234-5	60
Ag234-5	46	
Mhp3	Ag234-5	116
Ag234-5	101	
Mhp3	Ag234-5	170
Ag234-5	161	
Mhp3	Ag234-5	227
Ag234-5	221	
Mhp3	Ag234-5	287
Ag234-5	279	
Mhp3	Ag234-5	345
Ag234-5	337	
Mhp3	Ag234-5	401
Ag234-5	397	
Mhp3	Ag234-5	451
Ag234-5	456	
Mhp3	Ag234-5	
Ag234-5	457	

FIG. 2





Please type a plus sign (+) inside this box →

+

<b>DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63)</b>  <input checked="" type="checkbox"/> Declaration submitted with Initial Filing <input type="checkbox"/> Declaration Submitted after Initial Filing (surcharge 37 CFR 1.16 (e)) required)	<b>Attorney Docket Number</b>	PC10555A
	<b>First Named Inventor</b>	Kendall Wayne King
	<b>COMPLETE IF KNOWN</b>	
	<b>Application Number</b>	Not Yet Assigned
	<b>Filing Date</b>	Herewith
	<b>Group Art Unit</b>	Not Yet Assigned
	<b>Examiner Name</b>	Not Yet Assigned

**As a below named inventor, I hereby declare that:**

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

NUCLEIC ACIDS AND PROTEINS OF THE MYCOPLASMA HYOPNEUMONIAE MHP3 GENE AND USES THEREOF

(Title of the Invention)

the specification of which

☒ is attached hereto

OR

☐ was filed on (MM/DD/YYYY) \_\_\_\_\_ as United States Application Number or PCT International

Application Number \_\_\_\_\_ and was amended on (MM/DD/YYYY) \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?	
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto:

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below:

Application Number(s)	Filing Date (MM/DD/YYYY)	
60/156,602	09/29/1999	<input type="checkbox"/> Additional provisional application numbers are listed on a supplemental priority data sheet PTO/SB/02B sheet attached hereto.

Please type a plus sign (+) inside this box →

+

**DECLARATION ---- Utility or Design Patent Application**

I hereby claim the benefit under 35 U.S.C. 120 of any United States application(s), or 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 U.S.C. 1.56, which became available between the filing date of the prior application and the national or PCT International filing date of this application.

U.S. Parent Application Number or PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (if applicable)
60/156,602	09/29/1999	

☐ Additional U.S. or PCT International application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

☐ Customer Number  
or

Place Customer  
Number Bar Code  
Label here

☒ Registered practitioner(s) name/registration number listed below

Name	Registration Number	Name	Registration Number
Peter C. Richardson	27,526	A. Dean Olson	31,185
Allen J. Spiegel	25,749	Mervin E. Brokke	32,723
Paul H. Ginsburg	28,718	Valerie M. Fedowich	33,688
J. Trevor Lumb	28,567	Bryan C. Zielinski	34,462
James T. Jones	30,561	Robert T. Ronau	36,257
Gregg C. Benson	30,977	B. Timothy Creagan	39,156
Robert F. Sheyka	31,304	Alan L. Koller	37,371
Grover F. Fuller Jr.	31,760	Jolene W. Appleman	35,428
Karen DeBenedictis	32,977	Kristina L. Konstas	37,864
Lorraine B. Ling	35,251	Seth H. Jacobs	32,140
Garth Butterfield	36,997	Martha A. Gammill	31,820
Carl J. Goddard	39,203	Gregory P. Raymer	36,647
Raymond M. Speer	26,810	E. Victor Donahue	35,492
Jennifer A. Kispert	40,049	Roy F. Waldron	42,208
Israel Nissenbaum	27,582	Todd M. Crissey	37,807
Adrian G. Looney	41,406	Deborah A. Martin	44,222
A. David Joran	37,858	Jeffrey N. Myers	41,213
Lawrence C. Akers	28,587	Elsa Djuardi	45,963
Gabriel L. Kleiman	40,681	Michelle A. Sherwood	36,271
Donna R. Grossu	P-47,248		

☐ Additional registered practitioner(s) named on supplemental Registered Practitioner Information sheet PTO/SB/02C attached hereto.

Direct all correspondence to: ☐ Customer Number or Bar Code Label OR ☒ Correspondence address below

<b>Name</b>	Paul H. Ginsburg				
<b>Address</b>	Pfizer Inc				
<b>Address</b>	235 East 42nd Street, 20th Floor				
<b>City</b>	New York	<b>State</b>	New York	<b>Zip Code</b>	10017-5755
<b>Country</b>	United States Of America	<b>Telephone</b>	(212)573-2369	<b>Fax</b>	(212)573-1939

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

**Name of Sole or First Inventor:** ☐ A petition has been filed for this unsigned inventor

<b>Given Name (first and middle (if any))</b>				<b>Family Name or Surname</b>			
Kendall Wayne				King			
<b>Inventor's Signature</b>						<b>Date</b>	
<b>Residence: City</b>	Waterford	<b>State</b>	CT	<b>Country</b>	USA	<b>Citizenship</b>	USA
<b>Post Office Address</b>	13 Mallard Lane						
<b>Post Office Address</b>							
<b>City</b>	Waterford	<b>State</b>	CT	<b>Zip</b>	06385	<b>Country</b>	USA

☒ Additional inventors are being named on the \_\_\_\_\_, a supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto.

Please type a plus sign (+) inside this box →

+

<b>DECLARATION</b>	<b>ADDITIONAL INVENTOR(S) Supplemental Sheet</b>
--------------------	--

<b>Name of Additional Joint Inventor, if any:</b>		<input type="checkbox"/> A petition has been filed for this unsigned inventor					
Given Name (first and middle [if any])				Family Name or Surname			
Rebecca Anne				Madura			
<b>Inventor's Signature</b>						<b>Date</b>	
<b>Residence: City</b>	Westerly	<b>State</b>	RI	<b>Country</b>	USA	<b>Citizenship</b>	USA
<b>Post Office Address</b>	17 Stone Hill Drive						
<b>Post Office Address</b>							
<b>City</b>	Westerly	<b>State</b>	RI	<b>Zip</b>	02891	<b>Country</b>	USA

<b>Name of Additional Joint Inventor, if any:</b>		<input type="checkbox"/> A petition has been filed for this unsigned inventor					
Given Name (first and middle [if any])				Family Name or Surname			
Everett Lee				Rosey			
<b>Inventor's Signature</b>						<b>Date</b>	
<b>Residence: City</b>	Preston	<b>State</b>	CT	<b>Country</b>	USA	<b>Citizenship</b>	USA
<b>Post Office Address</b>	457 Route 164						
<b>Post Office Address</b>							
<b>City</b>	Preston	<b>State</b>	CT	<b>Zip</b>	06365	<b>Country</b>	USA

<b>Name of Additional Joint Inventor, if any:</b>		<input type="checkbox"/> A petition has been filed for this unsigned inventor					
Given Name (first and middle [if any])				Family Name or Surname			
<b>Inventor's Signature</b>						<b>Date</b>	
<b>Residence: City</b>		<b>State</b>		<b>Country</b>		<b>Citizenship</b>	
<b>Post Office Address</b>							
<b>Post Office Address</b>							
<b>City</b>		<b>State</b>		<b>Zip</b>		<b>Country</b>	

<b>Name of Additional Joint Inventor, if any:</b>		<input type="checkbox"/> A petition has been filed for this unsigned inventor					
Given Name (first and middle [if any])				Family Name or Surname			
<b>Inventor's Signature</b>						<b>Date</b>	
<b>Residence: City</b>		<b>State</b>		<b>Country</b>		<b>Citizenship</b>	
<b>Post Office Address</b>							
<b>Post Office Address</b>							
<b>City</b>		<b>State</b>		<b>Zip</b>		<b>Country</b>	

SEQUENCE LISTING

<110> King, Kendall W  
Madura, Rebecca A  
Rosey, Everett L

<120> NUCLEIC ACIDS AND PROTEINS OF THE MYCOPLASMA PNEUMONIAE  
mhp3 GENE AND USES THEREOF

<130> PC10555

<140>

<141>

<150> US 60/156,602

<151> 1999-09-29

<160> 41

<170> PatentIn Ver. 2.1

<210> 1

<211> 1692

<212> DNA

<213> Mycoplasma hyopneumoniae

<400> 1

```
gtttttgaat ataatagaaa atgtaaaata aaaattaatt tattaaaaaa taattgaaag 60
tcatcgtaat taaaacaatt aattaggaga acaactatga aaaaaaagat aaaatgaaat 120
aaattttcttg gcttaggctt agtttttccg ctttcagcaa tcgcgacaat ctctgccgga 180
tggtgggata aagaaacaac taaagaagaa aaatcagccg ataatcaaaa taagcaaadc 240
actgatgtct caaaaatttc aggactagtt aatgaacgaa aatccgaaat tatggccgca 300
aaagctgatg caaacaaaac ttttgggcta aatatggcaa ttgtaaccgc tgggtggaacg 360
gtaaatgata attcatttaa ccaatcaagt tgagaggcaa ttcaacaact tggcgctctt 420
actggagggtg agattacttc agtagatagt tcaactgctg aacttgaagg aaaatatagc 480
tcacttgcta ataccaacaa aaatgtttga gtactttctg gttttcaaca cgggtgatgcg 540
ttcacaagat gattaaaaat ccctgaaaat aagcaattat ttactgaaaa aaatattatc 600
atactcggaa ttgactgaac tgatactgaa aatgtaattc caacaggctc atatattaat 660
ttaacctata aaactgaaga agccggatga cttgcaggat atgcgaatgc ttcctttttg 720
gcaaaaaaat tcccaagtga tccaactaaa agatcagcaa ttgttatcgg tgggtgggatt 780
tcgccagctg taactgatct tatcgctggt tatctagccg gaattaaagc ttgaaatcta 840
aaaaattctg ataaaaaaac aaagataaca actgataaaa tcgagataaa tcttggggtt 900
gatgttcaag atacttcaac aaaagaaaga cttgaacaaa ttgcttcaaa agataaacct 960
tcaacactat tagctgtcgc tggaccactt actgaaattt tctcgatat aatcgcaaac 1020
caaaatgatc gttatctcat tgggtgttgac accgaccaat cacttgttta tacaaaaact 1080
aaaaataaat ttttcacctc aattttgaaa aatttaggtt actccgtttt cagcgttctt 1140
agtgatttat ataccaaaaa atcaaattca agaaatttag ccggctttga atttggtaaa 1200
aaaagtgcaa ccgtttatct tggaaataaa gacagggttg tcgatattgc tgatacttct 1260
ttagaaggca atgataaaaa actcgcaact gaagccattt ctgaagctaa aaaagaattt 1320
gaagaaaaaa ctaagacaat tcctgccgaa gaagttcgta aaactttaga aattccggaa 1380
atgcctgata aacaacctga taagcaacag gaaagcttag acaactaat taccgatatt 1440
aataaaaaat aagtaagaaa aaataacaat tttttaacat tatatctttt tttagagatt 1500
aattttcttc taatttgatt taatttaata taaaattata ttaaattaaa aaaataaaaa 1560
atccggacta tttttgttcc ggatttttta tttttgtgtt actatttaat ataattgata 1620
atcaggatta tgcaattgaa tttattcaag tctcgaaaaa atttggcagt ttttatgcca 1680
attacaaaat ag                                     1692
```

<211> 451

<212> PRT

<213> Mycoplasma hyopneumoniae

<400> 2

Phe Pro Leu Ser Ala Ile Ala Thr Ile Ser Ala Gly Cys Trp Asp Lys  
20 25 30

Thr Asp Val Ser Lys Ile Ser Gly Leu Val Asn Glu Arg Lys Ser Glu  
50 55 60

Ile Met Ala Ala Lys Ala Asp Ala Asn Lys His Phe Gly Leu Asn Met  
65 70 75 80

Ala Ile Val Thr Ala Gly Gly Thr Val Asn Asp Asn Ser Phe Asn Gln  
85 90 95

Ser Ser Trp Glu Ala Ile Gln Gln Leu Gly Ala Leu Thr Gly Gly Glu  
100 105 110

Ile Thr Ser Val Asp Ser Ser Thr Ala Glu Leu Glu Gly Lys Tyr Ser  
115 120 125

Ser Leu Ala Asn Thr Asn Lys Asn Val Trp Val Leu Ser Gly Phe Gln  
130 135 140

His	Gly	Asp	Ala	Phe	Thr	Arg	Trp	Leu	Lys	Ile	Pro	Glu	Asn	Lys	Gln
145					150					155					160

Leu Phe Thr Glu Lys Asn Ile Ile Ile Leu Gly Ile Asp Trp Thr Asp  
165 170 175

Thr Glu Asn Val Ile Pro Thr Gly Arg Tyr Ile Asn Leu Thr Tyr Lys  
180 185 190

Thr Glu Glu Ala Gly Trp Leu Ala Gly Tyr Ala Asn Ala Ser Phe Leu  
195 200 205

Ala Lys Lys Phe Pro Ser Asp Pro Thr Lys Arg Ser Ala Ile Val Ile  
210 215 220

Gly Gly Gly Ile Ser Pro Ala Val Thr Asp Phe Ile Ala Gly Tyr Leu  
225 230 235 240

Ala Gly Ile Lys Ala Trp Asn Leu Lys Asn Ser Asp Lys Lys Thr Lys  
245 250 255

Ile Thr Thr Asp Lys Ile Glu Ile Asn Leu Gly Phe Asp Val Gln Asp

	260		265		270
Thr Ser Thr	Lys Glu Arg Leu Glu Gln Ile Ala Ser	Lys Asp Lys Pro			
	275		280		285
Ser Thr Leu	Leu Ala Val Ala Gly Pro Leu Thr Glu	Ile Phe Ser Asp			
	290		295		300
Ile Ile Ala	Asn Gln Asn Asp Arg Tyr Leu Ile Gly	Val Asp Thr Asp			
	305		310		315
Gln Ser Leu	Val Tyr Thr Lys Thr Lys Asn Lys Phe	Phe Thr Ser Ile			
		325		330	335
Leu Lys Asn	Leu Gly Tyr Ser Val Phe Ser Val Leu	Ser Asp Leu Tyr			
		340		345	350
Thr Lys Lys	Ser Asn Ser Arg Asn Leu Ala Gly Phe	Glu Phe Gly Lys			
		355		360	365
Lys Ser Ala	Thr Val Tyr Leu Gly Ile Lys Asp Arg	Phe Val Asp Ile			
		370		375	380
Ala Asp Thr	Ser Leu Glu Gly Asn Asp Lys Lys Leu	Ala Thr Glu Ala			
		385		390	395
Ile Ser Glu	Ala Lys Lys Glu Phe Glu Glu Lys Thr	Lys Thr Ile Pro			
		405		410	415
Ala Glu Glu	Val Arg Lys Thr Leu Glu Ile Pro Glu	Met Pro Asp Lys			
		420		425	430
Gln Pro Asp	Lys Gln Gln Glu Ser Leu Asp Lys Leu	Ile Thr Asp Ile			
		435		440	445
Asn Lys Asn					
		450			

<210> 3

<211> 1263

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: mhp3  
manipulated for in vitro expression

<400> 3

```

atgtgggata aagaaacaac taaagaagaa aaatcagccg ataatcaaaa taagcaaadc 60
actgatgtct caaaaatttc aggactagtt aatgaacgaa aatccgaaat tatggccgca 120
aaagctgatg caaacaaaca ttttgggcta aatatggcaa ttgtaaccgc tgggtggaacg 180
gtaaatgata attcatttaa ccaatcargt tgggaggcaa ttcaacaact tggcgctctt 240
actggagggtg agattacttc agtagatagt tcaactgctg aacttgaagg aaaatatagc 300
tcacttgcta ataccaacaa aaatgttttg gtactttctg gttttcaaca cgggtgatgcg 360
ttcacaagat ggtaaaaaat cctgaaaaat aagcaattat ttactgaaaa aaatattatc 420
atactcggaa ttgactggac tgatactgaa aatgtaattc caacaggctc atataatta 480

```



```
<210> 5
<211> 602
<212> DNA
<213> Mycoplasma hyopneumoniae
<400> 5
```



```
<210> 6
<211> 200
<212> PRT
<213> Mycoplasma hyopneumoniae
```

<400>	6														
Met	Ile	Ile	Phe	Phe	Ser	Val	Asn	Asn	Cys	Leu	Phe	Ser	Gly	Ile	Phe
1				5					10					15	
Asn	His	Leu	Val	Asn	Ala	Ser	Pro	Cys	Trp	Lys	Pro	Glu	Ser	Thr	Gln
			20					25					30		
Thr	Phe	Leu	Leu	Val	Leu	Ala	Ser	Glu	Leu	Tyr	Phe	Pro	Ser	Ser	Ser
		35					40					45			
Ala	Val	Glu	Leu	Ser	Thr	Glu	Val	Ile	Ser	Pro	Pro	Val	Arg	Ala	Pro
	50					55					60				
Ser	Cys	Trp	Ile	Ala	Ser	Gln	Leu	Asp	Trp	Leu	Asn	Glu	Leu	Ser	Phe
65					70					75					80
Thr	Val	Pro	Pro	Ala	Val	Thr	Ile	Ala	Ile	Phe	Ser	Pro	Lys	Cys	Leu
				85					90					95	
Phe	Ala	Ser	Ala	Phe	Ala	Ala	Ile	Ile	Ser	Asp	Phe	Arg	Ser	Leu	Thr
			100					105					110		
Ser	Pro	Glu	Ile	Phe	Glu	Thr	Ser	Val	Ile	Cys	Leu	Phe	Trp	Leu	Ser
		115					120					125			
Ala	Asp	Phe	Ser	Ser	Leu	Val	Val	Ser	Leu	Ser	Gln	His	Pro	Ala	Glu
	130					135					140				
Ile	Val	Ala	Ile	Ala	Glu	Ser	Gly	Lys	Thr	Lys	Pro	Lys	Pro	Arg	Asn
145					150					155					160
Leu	Phe	His	Phe	Ile	Phe	Phe	Phe	Ile	Val	Val	Leu	Leu	Ile	Asn	Cys
				165					170					175	
Phe	Asn	Tyr	Asp	Asp	Phe	Gln	Leu	Phe	Phe	Asn	Lys	Leu	Ile	Phe	Ile
			180					185					190		
Leu	His	Phe	Leu	Leu	Tyr	Ser	Lys								
		195					200								

<210> 7  
<211> 14  
<212> PRT  
<213> Mycoplasma hyopneumoniae

<400> 7  
Ala Gly Xaa Trp Ala Lys Glu Thr Thr Lys Glu Glu Lys Ser  
1 5 10

<210> 8  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:  
Oligonucleotide

<400> 8  
Ala Trp Val Thr Ala Asp Gly Thr Val Asn  
1 5 10

<210> 9  
<211> 21  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:  
Oligonucleotide

<400> 9  
Ala Ile Val Thr Ala Asp Gly Thr Val Asn Asp Asn Lys Pro Asn Gln  
1 5 10 15

Trp Val Arg Lys Tyr  
20

<210> 10  
<211> 30  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:  
Oligonucleotide

<400> 10  
tgytgrgcna argaracnac naargargar

30

<210> 11

<211> 30  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:  
Oligonucleotide

<400> 11  
tgttgagcwa aagaaacwac waaagaagaa 30

<210> 12  
<211> 27  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:  
Oligonucleotide

<400> 12  
tgrgtnacng cngayggnac ngtnaay 27

<210> 13  
<211> 27  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:  
Oligonucleotide

<400> 13  
tgagtwacwg cwgatggwac wgtwaat 27

<210> 14  
<211> 26  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:  
Oligonucleotide

<400> 14  
rttnacngtn ccrtcngcng tnacyc 26

<210> 15  
<211> 26  
<212> DNA  
<213> Artificial Sequence

<220>

“Sequence”

<400> 15  
attsacsgts ccatcsgcsg tsactc 26

```
<220>
<223> Description of Artificial Sequence:
      Oligonucleotide

<400> 16
tttgagacat cagtgatttg c
```

```
<220>
<223> Description of Artificial Sequence:
        Oligonucleotide

<400> 17
gaacgaaaat ccgaaattat gg                                     22
```

```
<220>
<223> Description of Artificial Sequence:
        Oligonucleotide

<400> 18
ctatctactg aagaatctca cc
```

```
<220>
<223> Description of Artificial Sequence:
      Oligonucleotide

<400> 19
gtgatgccgt tcacaagatg                                     20
```

<210>	24
<211>	20
<212>	DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:  
Oligonucleotide

<400> 24

gaaatgcctg ataaacaacc

20

<210> 25

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:  
Oligonucleotide

<400> 25

cttcagaaat ggcttcagtt gc

22

<210> 26

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:  
Oligonucleotide

<400> 26

gctagataac cagcgataaa atcag

25

<210> 27

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:  
Oligonucleotide

<400> 27

tgcataatcc tgatttatc

19

<210> 28

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:  
Oligonucleotide

Sequence 226

Year	Age	Sex	Location	Species	Number	Notes
1980	10	M	...	...	...	...
1981	11	F	...	...	...	...
1982	12	M	...	...	...	...
1983	13	F	...	...	...	...
1984	14	M	...	...	...	...
1985	15	F	...	...	...	...
1986	16	M	...	...	...	...
1987	17	F	...	...	...	...
1988	18	M	...	...	...	...
1989	19	F	...	...	...	...
1990	20	M	...	...	...	...
1991	21	F	...	...	...	...
1992	22	M	...	...	...	...
1993	23	F	...	...	...	...
1994	24	M	...	...	...	...
1995	25	F	...	...	...	...
1996	26	M	...	...	...	...
1997	27	F	...	...	...	...
1998	28	M	...	...	...	...
1999	29	F	...	...	...	...
2000	30	M	...	...	...	...
2001	31	F	...	...	...	...
2002	32	M	...	...	...	...
2003	33	F	...	...	...	...
2004	34	M	...	...	...	...
2005	35	F	...	...	...	...
2006	36	M	...	...	...	...
2007	37	F	...	...	...	...
2008	38	M	...	...	...	...
2009	39	F	...	...	...	...
2010	40	M	...	...	...	...
2011	41	F	...	...	...	...
2012	42	M	...	...	...	...
2013	43	F	...	...	...	...
2014	44	M	...	...	...	...
2015	45	F	...	...	...	...
2016	46	M	...	...	...	...
2017	47	F	...	...	...	...
2018	48	M	...	...	...	...
2019	49	F	...	...	...	...
2020	50	M	...	...	...	...

<210> 33  
 <211> 28  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:  
 Oligonucleotide

<400> 33  
 ctattttgta attggcataa aaactgcc 28

<210> 34  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:  
 Oligonucleotide

<400> 34  
 gataaaatgg aataaatttc ttgg 24

<210> 35  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:  
 Oligonucleotide

<400> 35  
 caggttggga ggcaattcaa c 21

<210> 36  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:  
 Oligonucleotide

<400> 36  
 caaaaatggt tgggtacttt ctgg 24

<210> 37  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence

Sequence



<223> Description of Artificial Sequence:  
Oligonucleotide

21

<213> Artificial Sequence

<223> Description of Artificial Sequence:  
Oligonucleotide

22

<213> Artificial Sequence

<223> Description of Artificial Sequence:  
Oligonucleotide

22

<213> Artificial Sequence

<223> Description of Artificial Sequence:  
Oligonucleotide

24

<213> Mycoplasma hyorhinis

Met Asn Phe Lys Lys Ser Leu Leu Phe Leu Thr Gly Thr Ile Ser Thr  
1 5 10 15

Val Ala Ser Val Ala Thr Phe Val Ser Cys Gly Glu Thr Asp Lys Glu

20										25										30																																			
Gly	Lys	Ile	Ile	Arg	Ile	Phe	Asp	Asn	Ser	Phe	Val	Lys	Asp	Arg	Gln																																								
		35					40					45																																											
Ala	Glu	Ile	Glu	Lys	Ala	Lys	Asn	Phe	Asp	Phe	Asn	Thr	Val	Leu	Leu																																								
	50					55					60																																												
Thr	Ala	Gly	Gly	Thr	Val	Gln	Asp	Lys	Ser	Phe	Asn	Gln	Ser	Ile	Trp																																								
	65				70					75					80																																								
Glu	Ala	Val	Leu	Glu	His	Tyr	Asp	Gln	Ile	Glu	Lys	Thr	Thr	Asn	Leu																																								
			85						90					95																																									
Asp	Arg	Val	Ser	Gln	Glu	Thr	Asn	Asn	Gln	Ser	Glu	Leu	Ile	Gly	Lys																																								
			100					105					110																																										
Tyr	Lys	Asn	Phe	Leu	Asn	Gly	Asn	Lys	Asn	Val	Trp	Ile	Leu	Thr	Gly																																								
		115					120					125																																											
Phe	Gln	Gln	Gly	Gln	Glu	Phe	Pro	Lys	Phe	Leu	Lys	Gln	Thr	Asp	Ser																																								
	130					135					140																																												
Asn	Gly	Lys	Lys	Tyr	Ser	Asp	Leu	Leu	Ala	Glu	Lys	Lys	Val	Ile	Ile																																								
	145				150				155					160																																									
Val	Ala	Val	Asp	Trp	Asp	Leu	Ser	Lys	Glu	Asp	Lys	Asp	Leu	Ile	Lys																																								
			165					170					175																																										
Ala	Gly	His	Phe	Ile	Ser	Leu	Leu	Tyr	Lys	Thr	Glu	Glu	Ala	Gly	Phe																																								
			180					185					190																																										
Ile	Ala	Gly	Tyr	Ala	Ser	Ser	Lys	Phe	Leu	Ala	Tyr	Lys	Phe	Pro	Asn																																								
		195					200					205																																											
Asp	Glu	Ala	Lys	Arg	Thr	Ile	Ala	Pro	Phe	Gly	Gly	Gly	His	Gly	Ala																																								
	210					215					220																																												
Gly	Val	Thr	Asp	Phe	Ile	Ala	Gly	Phe	Leu	Ala	Gly	Ile	Ala	Lys	Tyr																																								
	225				230					235				240																																									
Asn	Asn	Asp	Asn	Pro	Thr	Ala	Lys	Val	Thr	Ile	Ser	Asp	Asn	Asn	Ile																																								
			245					250					255																																										
Asn	Ile	Asp	Thr	Gly	Phe	Ile	Ser	Asn	Asp	Lys	Thr	Ala	Thr	Phe	Ile																																								
		260						265					270																																										
Asn	Gly	Ile	Val	Asn	Lys	Ser	Ser	Leu	Val	Leu	Pro	Val	Ala	Gly	Ser																																								
		275				280						285																																											
Leu	Thr	Ser	Ser	Val	Val	Asp	Ala	Ile	Lys	Lys	Ser	Asn	Lys	Asp	Thr																																								
	290				295							300																																											
Lys	Tyr	Leu	Ile	Gly	Val	Asp	Thr	Asp	Gln	Ser	Lys	Ile	Phe	Ser	Pro																																								
	305				310				315						320																																								
Ala	Thr	Val	Phe	Phe	Thr	Ser	Ile	Glu	Lys	His	Leu	Gly	Arg	Thr	Ile																																								

000000"01e92960

325								330				335			
Tyr	Gln	Val	Leu	Thr	Asp	Ile	Trp	Leu	Lys	Lys	Glu	Asp	Ser	Lys	Phe
			340					345					350		
Leu	Gly	Ser	Phe	Arg	Ser	Phe	Lys	Leu	Thr	Asn	Pro	Ala	Asn	Ala	Thr
			355				360					365			
Val	Tyr	Lys	Gly	Ile	Ser	Asp	Asp	Phe	Val	Gly	Val	Ser	Asn	Ser	Thr
			370				375					380			
Val	Ala	Asp	Ala	Asp	Lys	Val	Lys	Ala	Gln	Glu	Phe	Leu	Asn	Glu	Ala
385					390					395					400
Thr	Ala	Asp	Phe	Lys	Lys	Gln	Ile	Gln	Ala	Asn	Pro	Thr	Asn	Tyr	Lys
				405					410					415	
Ser	Val	Leu	Gly	Ile	Pro	Thr	Met	Leu	Ile	Asn	Asp	Asn	Asp	Ala	Lys
			420					425					430		
Asp	Asn	Glu	Lys	Ala	Ser	Leu	Phe	His	Phe	Asp	Asn	Trp	Gln	Thr	Tyr
			435				440					445			
Trp	Ala	Phe	His	Ser	Arg	Phe	Ile	Asn							
			450				455								